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Definitions & Key Indicator Descriptions 
Acceptable storage conditions for medicines:  A wholesaler or outlet is considered to have 
acceptable storage conditions for medicines if it is in compliance with all the following three 
standards: (1) medicines are stored in a dry area; (2) medicines are protected from direct sunlight; 
and (3) medicines are not kept on the floor. 
Adult equivalent treatment dose (AETD):  The number of milligrams of an antimalarial treatment 
needed to treat a 60kg adult whereby all dosage types found (tablet, suspension, syrup, etc.) are 
converted regardless of their original presentation (whether for child or adult).  The number of 
mg/kg used to determine the dose is defined as what is recommended for a particular drug 
combination in the treatment guidelines for uncomplicated malaria in areas of low drug resistance 
issued by the WHO.  Where this does not exist, a product manufacturer’s treatment guidelines are 
consulted.  See Appendix 6.3 for additional details  
Antimalarial combination therapy:  The use of two or more classes of antimalarial drugs/molecules 
in the treatment of malaria that have independent modes of action. 
Antimalarial:  Any medicine recognized by the WHO for the treatment of malaria.  Medicines used 
solely for the prevention of malaria were excluded from analysis in this report. 
Artemisinin and its derivatives:  Artemisinin is a plant extract used in the treatment of malaria.  The 
most common derivatives of artemisinin used to treat malaria are artemether, artesunate, and 
dihydroartemisinin. 
Artemisinin monotherapy (AMT):  An antimalarial medicine that has a single active compound, 
where this active compound is artemisinin or one of its derivatives. 
Artemisinin-based Combination Therapy (ACT):  An antimalarial that combines artemisinin or one of 
its derivatives with an antimalarial or antimalarials of a different class.  Refer to combination therapy 
(below).   
Availability of any antimalarial or RDTs:  The proportion of wholesalers in which the specified 
antimalarial medicine or RDT was found on the day of the survey, based upon an audit conducted by 
the interviewer.  For indicators of availability, all wholesalers who were eligible to participate after 
screening (i.e. had any antimalarial or RDT in stock at present or at any point in the 3 months prior to 
interview) are included in the denominator. 
Booster sample:  A booster sample is an extra sample of units (or in this case outlets) of a type not 
adequately represented in the main survey, but which are of special interest.  In Uganda the 
ACTwatch Outlet Survey included a booster sample of all public health facilities in the entire county 
in which a selected subcounty/parish was located; and registered pharmacies in the entire district in 
which a selected subcounty/parish was located. 
Censused sub-district:  Subcounties (or parishes, in the case of Kampala) where field teams 
conducted a full census of all outlets with the potential to sell antimalarials as part of the ACTwatch 
Outlet Survey. 
Combination therapy:  The use of two or more classes of antimalarial drugs/molecules in the 
treatment of malaria that have independent modes of action. 
Credit to consumers:  A wholesaler is considered to provide credit to consumers based on the 
response of the wholesaler.  
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Distribution chain:  The chain of businesses operating from the factory gate/port of entry down to 
the retail level.  Also sometimes referred to as downstream value chain.  In this report, the terms 
distribution chain and supply chain are used interchangeably.  More specifically, the ‘private 
commercial sector distribution chain’ refers to any type of public or private wholesaler who served 
private commercial outlets, as well as private commercial wholesalers who served public sector or 
NGO outlets so that any transactions between public, NGO and private commercial sectors are 
noted. 
Dosing/treatment regimen:  The posology or timing and number of doses of an antimalarial used to 
treat malaria. This schedule often varies by patient weight. 
First-line treatment:  The government recommended treatment for uncomplicated malaria.  
Uganda’s first-line treatment for Plasmodium falciparum malaria is artemether-lumefantrine, 
20mg/120mg. 
Inter-quartile range (IQR):  A descriptive statistic that provides a measure of the spread of the 
middle 50% of observations.  The lower bound value of the range is defined by the 25th percentile 
observation and the upper bound value is defined by the 75th percentile observation. 
Mark-up:  The difference between the price at which a product is purchased, and that at which it is 
sold.  Sometimes also referred to as margin.  In this report, the terms mark-up and margin are used 
interchangeably.  May be expressed in absolute or percent terms.  Because it is common for 
wholesalers to vary their prices with the volumes they sell, minimum, mid and maximum mark-ups 
were calculated in this report using price data collected from interviewees.  Key findings on price 
mark-ups at the wholesale level are reported using mid mark-up data.  As maximum and minimum 
selling prices were not collected at the retail level, only one set of absolute and percent retail mark-
ups is calculated. 
Absolute mark-up:  The absolute mark-up is calculated as the difference between the selling 
price and the purchase price per full-course adult equivalent treatment dose.  In this report, 
absolute mark-ups are reported in US dollars.  The average exchange rate during the data 
collection period for wholesale purchase prices (13 February to 6 April 2009) was 2049.16 
Uganda Shillings (UGX) to US$1; the average exchange rate during the data collection period 
for retail purchase prices (16 March to 7 April 2009) was 2113.53 Uganda Shillings (UGX) to 
US$1 (www.oanda.com). 
Percent mark-up:  The percentage mark-up is calculated as the difference between the 
selling price and the purchase price, divided by the purchase price. 
Maximum mark-up:  For wholesale level only, the absolute and percent maximum mark-ups 
are calculated as above using the difference between maximum wholesale selling price and 
the wholesale purchase price. 
Minimum mark-up:  For wholesale level only, the absolute and percent minimum mark-ups 
are calculated as above using the difference between minimum wholesale selling price and 
the wholesale purchase price. 
Mid mark-up:  For wholesale level only, the absolute and percent mid mark-ups are 
calculated as above using the difference between the average wholesale selling price (i.e. 
the mid-point between the maximum and minimum wholesale selling price) and wholesale 
purchase price.  
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Median:  A descriptive statistic given by the middle (or 50th percentile) value of an ordered set of 
values (or the average of the middle two in a set with an even number of values), which is an 
appropriate measure of central tendency of a skewed distribution of continuous data. 
Monotherapy:  An antimalarial medicine that has a single mode of action.  This may be a medicine 
with a single active compound or a synergistic combination of two compounds with related 
mechanisms of action.  
Non-artemisinin therapy (nAT):  An antimalarial treatment that does not contain artemisinin or any 
of its derivatives. 
Non-WHO-prequalified ACTs:  ACTs that do not meet acceptable standards of quality, safety and 
efficacy as assessed by the WHO Prequalification of Medicines Programme, or have yet to be 
assessed as such.  (See WHO-prequalified ACTs below)  
Oral artemisinin monotherapy:  Artemisinin or one of its derivatives in a dosage form with an oral 
route of administration.  These include tablets, suspensions, and syrups and exclude suppositories 
and injections.   
Outlet:  Any point of sale or provision of a commodity to an individual.  Outlets are not restricted to 
stationary points of sale and may include mobile units or individuals.  Refer to Appendix 6.3 for a 
description of the outlet types visited as part of the ACTwatch Outlet Survey.   
Purchase price:  The price paid by businesses (i.e. wholesalers or outlets) for their most recent 
purchase of an antimalarial product from their suppliers.  This is different from selling price (see 
below).  Prices are reported in terms of full adult equivalent treatment dose treatment.  Prices are 
shown in US dollars.  The average exchange rate during the data collection period for wholesale 
purchase prices (13 February to 6 April 2009) was 2049.16 Uganda Shillings (UGX) to US$1; the 
average exchange rate during the data collection period for retail purchase prices (16 March to 7 
April 2009) was 2113.53 Uganda Shillings (UGX) to US$1 (www.oanda.com). 
Rapid-Diagnostic Test (RDT) for malaria:  Malaria rapid diagnostic tests, sometimes called 
"dipsticks" or malaria rapid diagnostic devices, assist in the diagnosis of malaria by providing 
evidence of the presence of malaria parasites in human blood. RDTs do not require laboratory 
equipment, and can be performed and interpreted by non-clinical staff. 
Screening/Eligibility criteria:  The set of requirements that must be satisfied before the full 
questionnaire is administered. In the ACTwatch Supply Chain Survey, a wholesaler met the screening 
criteria if (1) they had any antimalarial or RDTs in stock at the time of the survey visit, or (2) they 
report having stocked either antimalarials or RDTs in the past three months. 
Second-line treatment:  The government recommended second-line treatment for uncomplicated 
malaria.  Uganda’s second-line treatment for Plasmodium falciparum malaria is quinine. 
Selling price:  The price paid by customers to purchase antimalarials.  For outlets, these customers 
are patients or caretakers; for wholesalers, these customers are other businesses or health facilities.  
Because it is common for wholesalers to vary their selling prices depending on the volumes 
purchased by the customer, data on maximum and minimum selling price charged for one unit by 
wholesalers were collected for each antimalarial product type in stock at the time of interview.   
Stock outs of ACT:  Reported in the affirmative as the percentage of interviewed wholesalers who 
reported to have always had at least one ACT in stock over the past 3 months.  All eligible (see 
Screening criteria above) wholesalers who were successfully interviewed were included in the 
denominator. 
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Sub-district (SD):  The primary sampling unit, or cluster, for the ACTwatch Outlet Survey is generally 
defined in Uganda as the subcounty, which typically hosts a population size of approximately 10,000 
to 15,000 inhabitants.  However, in Kampala where the subcounty populations far exceed this 
approximate size, a smaller sub-division, the parish, has been used as the sub-district. 
Top selling antimalarial:  The antimalarial with the largest volume of adult equivalent treatment 
doses sold or distributed in the past week as reported by individual wholesalers.   
Volumes:  Volumes of antimalarials sold in the previous week are reported in terms of full-course 
adult equivalent treatment doses (or AETDs; see above for description). 
WHO-prequalified ACTs:  ACTs that meet acceptable standards of quality, safety and efficacy as 
assessed by the WHO Prequalification of Medicines Programme.  This is a service provided by WHO 
to guide bulk medicine purchasing of international procurement agencies and countries for 
distribution in resource limited settings, often using funds for development aid (e.g. Global Fund 
grants).  More details on the list of prequalified medicines and the prequalification process may be 
found on the WHO website at: http://www.who.int/mediacentre/factsheets/fs278/en/index.html.  
Wholesalers:  Businesses that supply other businesses, which may include retailers or other 
wholesalers.  In this report, wholesalers are classified further into more specific categories defined 
by the type of businesses that they supply.  As some wholesalers will supply different types of 
businesses (e.g. both retail outlets and other wholesalers), these categories are not mutually 
exclusive and such wholesalers may appear in multiple categories.  These are defined below. 
Terminal wholesalers:  Wholesalers that supply retail outlets directly.  For example, 
wholesaler X is a terminal wholesaler if it supplies antimalarials to pharmacies and drug 
shops from which patients buy medicines.  Terminal wholesalers may supply retail outlets 
only, but may also supply other wholesalers. 
Intermediate-1 wholesalers:  Wholesalers that supply terminal wholesalers directly.  
Intermediate-1 wholesalers may supply terminal wholesalers only, but may also supply other 
types of wholesalers (such as other intermediate-1 wholesalers) and retail outlets. 
Intermediate-2 wholesalers:  Wholesalers that supply Intermediate-1 wholesalers directly.  
Intermediate-2 wholesalers may supply Intermediate-1 wholesalers only, but may also 
supply other types of wholesalers (such as terminal wholesalers) and retail outlets.  
Intermediate-3 wholesalers:  Wholesalers that supply Intermediate-2 wholesalers directly.  
Intermediate-3 wholesalers may supply Intermediate-2 wholesalers only, but may also 
supply other types of wholesalers (such as intermediate-1 or terminal wholesalers) and retail 
outlets.  
Intermediate-4 wholesalers:  Wholesalers that supply Intermediate-3 wholesalers directly.  
Intermediate-4 wholesalers may supply Intermediate-3 wholesalers only, but may also 
supply other types of wholesalers (such as intermediate-2, intermediate-1 or terminal 
wholesalers) and retail outlets.  
Wholesalers supplying retailers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as a terminal wholesaler. 
Wholesalers supplying wholesalers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as operating at an intermediate 
level of the supply chain (e.g. in this report, intermediate-1, intermediate-2 and 
intermediate-3 wholesalers).  
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Abbreviations 
ACT artemisinin-based combination therapy 
AETD adult equivalent treatment dose 
AL artemether lumefantrine  
AMFm Affordable Medicine Facility - malaria 
AMT artemisinin monotherapy 
AR artemether 
AS artesunate 
ASAQ aretesunate-amodiaquine 
ASMQ artesunate and mefloquine 
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CQ chloroquine 
DHA dihydroartemisinin 
DHA+PP dihydroartemisinin and piperaquine 
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IPT intermittent preventive treatment of malaria 
IQR inter-quartile range  
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ITN insecticide treated net 
JMS Joint Medical Stores 
LSHTM London School of Hygiene & Tropical Medicine  
MEC mutually-exclusive category of wholesalers 
MOH Ministry of Health 
MQ mefloquine 
nAT non-artemisinin therapy 
NDA National Drug Authority, Uganda 
NGO non-governmental organisation 
NMCP National Malaria Control Programme 
NMS National Medical Stores 
OS ACTwatch Outlet Survey 
OTC over-the-counter 
PACE Program for Accessible Health, Communication and Education (Uganda) 
Pf Plasmodium falciparum  
PMI US President’s Malaria Initiative 
POM prescription only medicine 
PPS probability proportional to size 
PSI Population Services International  
RDT rapid diagnostic test 
SP sulphadoxine pyrimethamine 
WHO World Health Organization  
WS Wholesaler 
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Executive Summary 
Background 
In Uganda, as in many low-income countries, private commercial providers play an important role in 
the treatment of malaria.  To design effective interventions for improved access to accurate 
diagnosis and effective malaria treatment, there is a need to understand retailer behaviour and 
identify the factors that influence their stocking and pricing decisions.  Private commercial retailers 
are the last link in a chain of manufacturers, importers and wholesalers and their supply sources are 
likely to have an important influence on the price and quality of malaria treatment that consumers 
can access.  However, there is limited rigorous evidence on the structure and operation of the 
distribution chain for antimalarial drugs that serves the retail sector. 
 
The ACTwatch Supply Chain Study, one of the ACTwatch project components, aims to address this 
gap by conducting quantitative and qualitative studies on distribution chains for antimalarials in the 
ACTwatch countries (Uganda, Cambodia, Zambia, Nigeria, Benin, Madagascar and the Democratic 
Republic of Congo (DRC)).  Other elements of ACTwatch include Retail Outlet and Household Surveys 
led by Population Services International (PSI).  This report presents the results of a cross-sectional 
survey of antimalarial drug wholesalers conducted in Uganda between February and April 2009. 
 
Methods 
The Supply Chain survey was implemented by the London School of Hygiene & Tropical Medicine 
(LSHTM), with support from the Program for Accessible Health, Communication and Education 
(PACE) Uganda/PSI, following shortly after the ACTwatch Outlet Survey conducted by PSI.  
Wholesalers operating at different levels of the supply chain that served a representative sample of 
Uganda’s malaria endemic and epidemic-prone areas were sampled through a bottom-up approach 
during which wholesalers were identified by their customers until the top of the chain was reached.  
For this purpose, all 38 sub-districts from the ACTwatch Outlet Survey were included in the sample.  
The sampling procedure used the list of the two top antimalarial wholesale sources (termed the 
terminal wholesalers) reported by each antimalarial retail outlet that participated in the Outlet 
Survey.  From these data a list of all terminal wholesalers mentioned was created.  All these terminal 
wholesalers were visited and invited to participate in the Supply Chain survey.  Wholesalers were 
eligible to participate if they met the following screening criteria: they had either an antimalarial or 
rapid diagnostic test (RDT) in stock at the time of interview, or they reported to have stocked either 
antimalarials or RDTs in the three months prior to interview.  During the interview, eligible 
wholesalers were also asked about their two top supply sources for antimalarials (termed the 
intermediate-1 wholesalers).  From these data, we created a list of all intermediate-1 wholesalers 
mentioned.  All these intermediate-1 wholesalers were visited and invited to participate in the 
Supply Chain survey, during which, as at previous levels, they were asked about their two top supply 
sources for antimalarials (termed the intermediate-2 wholesalers).  This process was repeated until 
the factory gate or port of entry was reached. 
 
The supply chain survey collected data on the structure of the private commercial sector supply 
chain; wholesaler characteristics and business practices; wholesale outlet licensing and inspection; 
wholesaler knowledge, qualifications and training; and wholesale availability, purchase prices and 
mark-ups for antimalarials and RDTs.  Retail outlets’ purchase prices and mark-ups for antimalarials 
collected during the Outlet Survey are also presented in this report as they form the last step of the 
supply chain before antimalarials reached patients/caretakers and are therefore relevant to the 
study of the distribution chain. 
 
 
2 
Results 
 
STRUCTURE OF THE SUPPLY CHAIN: A total of 142 antimalarial wholesalers were identified, and 129 
interviews were conducted. The maximum number of steps from manufacturers’ factory gate to 
retail outlets was 6 with wholesalers operating across 5 overlapping levels: intermediate-4 (INT 4 
WS), intermediate-3 (INT 3 WS), intermediate-2 (INT 2 WS), intermediate-1 (INT 1 WS) and terminal 
(TERMINAL WS) levels. (Figure 1)  However, most antimalarials were likely to go through 3 steps 
from manufacturer to retailer (or 4 steps from manufacturer to end-user) as 81.4% of all wholesalers 
supplied antimalarials to retailers, and of these, only 3.9% were observed to purchase antimalarials 
directly from manufacturers as one of their two top suppliers. As a result, the supply chain is shaped 
as a pyramid with a particularly broad base. Each red dot on Figure 1 represents a mutually exclusive 
group of wholesalers and the array of arrows emanating from them describes the specific supply 
chain levels that each wholesaler group serves.  Their percentage share is attached to each group.  
The dashed line from manufacturer to retailer indicates that there may be some retailers who 
purchase antimalarials directly from manufacturers; however, these transactions were rare.  Figure 2 
illustrates how the overlapping analytical categories used throughout this report are derived from 
the different mutually exclusive wholesaler categories depicted in Figure 1. 
 
Figure 1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive 
wholesaler category 
  
Note:  WS: wholesaler;  INT: intermediate 
Figure 2: Representation of the antimalarial 
distribution chain showing the overlap between 
wholesaler categories used for analysis 
 
 
 
 
 
  
3 
WHOLESALER CHARACTERISTICS:  Wholesalers at different levels of the supply chain differed in their number 
of years of operation and in size, with wholesalers supplying other wholesalers being in business for longer and 
being larger (median of 9 years and 8 employees) compared to wholesalers that supplied retailers (median of 6 
years in business and 5 employees).  All wholesalers reported employing a member of staff with a health 
qualification, the most commonly reported being nurses/midwives (90%), followed by pharmacists (88.3%), 
and pharmacy assistants (24%).  Nearly all wholesalers (99%) reported to have been visited by a 
pharmaceutical inspector in the past year, although a smaller proportion (92%) were observed to store their 
antimalarials appropriately (off the floor, in dry areas and out of direct sunlight), or were observed to have an 
up-to-date license from the National Drug Authority (82%).  Three-quarters of all wholesalers interviewed had 
provided credit facilities to their customers, and only 32% reported delivering antimalarial orders.  
 
AVAILABILITY OF ANTIMALARIALS & RDTS:  Nearly all wholesalers (99%) had at least one antimalarial in stock 
at the time of interview, 88% had ACT in stock, and 74% stocked the ACT artemether+lumefantrine (AL, the 
recommended first line treatment for uncomplicated Pf malaria in Uganda).  Availability of other antimalarial 
drugs was comparable to that of ACT, with oral artemisinin monotherapies (AMT) being stocked by 76% of all 
wholesalers, and non-artemisinin therapies (nAT) by 89% of wholesalers. Half of all wholesalers (52%) stocked 
non-oral AMTs and RDTs were stocked by less than a fifth (18%) of wholesalers. 
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ANTIMALARIAL & RDT SALES VOLUMES:  The median number of adult equivalent treatment doses (AETDs) of 
antimalarials sold the week preceding the survey was greatest for nATs (304.9), followed by ACTs (22.0) and  
smallest for AMT (15.0). AMT sales volumes were dominated by tablets. These figures reflect the fact that, 
among wholesalers who sold antimalarials the week before the survey (n=127), more than a third (36%) 
reported the nAT sulphadoxine-pyrimethamine (SP) to be their top selling antimalarial, followed by other nATs 
chloroquine (18%) and quinine (12%), while only 10% reported AL, the government-recommended first-line 
ACT treatment, as their top selling antimalarial. The volume of RDTs flowing down the supply chain was low, 
with wholesalers reporting a median of 10 RDTs sold in the preceding 7 days. 
 
WHOLESALE PURCHASE PRICES:  The median wholesale purchase price (i.e. the price paid by wholesalers to 
purchase stock from their suppliers) per AETD varied across antimalarial drug categories.  Overall, AMTs had 
the highest median purchase price per AETD (US$ 6.34), followed by ACTs (US$ 4.39); while nATs had a lower 
median purchase price of US$ 1.17. However, median purchase prices were comparable for ACTs and AMTs for 
similar dosage forms: for tablets the median purchase price was US$ 4.14 for ACT and US$ 5.08 for AMT; and 
for oral liquids, US$ 12.69 for ACT and US$ 10.15 for AMT. Among wholesalers, the median purchase price for 
the government recommended first-line treatment, AL (US$ 3.05), was more than 20 times the wholesale 
purchase price of SP (US$ 0.15); and the median purchase price for the government recommended treatments 
for severe malaria was US$ 4.61 per AETD for injectable quinine and US$ 9.27 for injectable artemether.  The 
wholesale purchase price for RDTs was much lower than that for ACTs at US$ 0.78 per test. 
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WHOLESALE MARK-UPS FOR ANTIMALARIALS & RDTS:  The median mid percent mark-ups were relatively low 
and consistent across antimalarial categories: 14% on ACTs, 15% on AMTs and 18% on nATs.  Wholesale 
percent mark-ups were also fairly consistent across dosage forms. In absolute terms, mark-ups per AETD were 
the highest on AMT (US$ 0.94), followed by ACT (US$ 0.59) and nAT (US$ 0.20), corresponding to the 
differences in purchase prices across drug categories.  For similar reasons, variation in absolute mark-up was 
also seen across dosage forms within a drug category, with injectables tending to have the highest absolute 
mark-ups, followed by oral liquids and then tablets (except for AMT, where oral liquids were observed to have 
higher absolute mark-ups than injectables).  For example, the median mid absolute mark-up on nAT injectables 
was US$ 1.02, compared to US$ 0.36 for oral liquids, and US$ 0.06 for tablets.  For AL, the median mid percent 
mark-up was 17% (corresponding to a median mid absolute mark-up of US$ 0.52 per AETD), compared to 23% 
for SP (corresponding to a median mid absolute mark-up of US$ 0.04 per AETD).  For injectable quinine, the 
median mid percent mark-up was 25% (corresponding to a median mid absolute mark-up of US$ 0.73 per 
AETD), and 12% (corresponding to a median mid absolute mark-up of US$ 1.00 per AETD) for injectable 
artemether. For RDTs, the median wholesale percent mark-up was 20%, equivalent to US$ 0.15 in absolute 
terms. 
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RETAIL PURCHASE PRICES:  Similar to the wholesale level, median retail purchase prices (i.e. the price paid by retailers to purchase stock from their suppliers) 
per AETD varied across antimalarial drug categories.  In general, AMTs were observed to have the highest median retail purchase prices per AETD and 
displayed little variation across retailer categories (ranging from US$ 6.06 at private health facilities and drug stores to US$ 6.43 at pharmacies), while nATs 
had the lowest median retail purchase prices per AETD and also displayed little variation across retailer categories (ranging from US$ 0.59 at drug stores to 
US$ 0.79 at pharmacies).  ACTs displayed the greatest variation in median retail purchase prices across retailer categories, which ranged from US$ 2.27 in 
drug stores to US$ 6.39 in pharmacies.  Pharmacies tended to have paid higher purchase prices for antimalarials compared to private health facilities and 
drug stores, although the differences in median purchase prices across retailer categories for AMTs and nATs were small. Pharmacies also tended to have 
paid similar prices to purchase ACT and AMT tablets (US$ 5.32 and US$ 5.68), but higher prices to purchase ACT oral liquid dosage forms. In private health 
facilities and drug stores, median purchase prices for ACT tablets and oral liquids were lower than those for AMT tablets and oral liquids. Across retailer 
categories, injectable nATs were observed to have the highest median retail purchase prices per AETD (ranging from US$ 4.83 at pharmacies to US$ 4.97 at 
private health facilities and drug stores) compared to other nAT dosage forms. Median retail purchase prices for injectable AMTs were also high (ranging 
from US$ 9.46 at private health facilities to US$ 11.36 at drug stores), but were similar to those paid for AMTs in oral liquid form (ranging from US$ 6.81 at 
pharmacies to US$ 11.36 at private health facilities and drug stores). Data were collected by PSI during the ACTwatch Outlet Survey. 
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RETAIL MARK-UPS FOR ANTIMALARIALS:  Median mid percent mark-ups among retailers tended to be higher compared to those observed among 
wholesalers.  For ACTs, the median mark-up varied little across retailer category from 33% to 46%; for AMT, median mark-up ranged between 33% at drug 
stores and 60% at private health facilities; and for nAT, between 67% at pharmacies and drug stores, and 88% at private health facilities.  Mark-ups above 
100% were commonly observed in drug stores and for nATs across all retailer categories.  Variation in absolute mark-ups was also observed across 
antimalarial and retailer categories, corresponding closely with variations in purchase price: mark-ups on ACTs ranged between US$ 0.95 and US$ 2.37; on 
AMT between US$ 2.84 and US$ 5.00; and on nAT between US$ 0.44 and US$ 0.74. For AL, median mid percent mark-up ranged between 33% (US$ 2.37) at 
pharmacies and 43% (US$ 1.89) at private health facilities, while the median mid percent mark-up for SP ranged between 100% (US$ 0.47) at pharmacies and 
200% (US$ 0.35) at private health facilities. For injectable quinine, median mid percent mark-up ranged between 25% (US$ 1.49) at pharmacies and 150% 
(US$ 6.16) at private health facilities; and for injectable artemether, median mid percent mark-up ranged between 20% (US$ 3.79) at drug stores and 70% 
(US$ 8.52) at private health facilities. Data were collected by PSI during the ACTwatch Outlet Survey. 
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Conclusions 
 
This report has presented a number of important new insights into the private sector market and 
distribution chain for antimalarial drugs in Uganda.  The distribution chain had a pyramid shape comprised of 
multiple levels, with a relatively broad base and narrow top.  While we observed wholesalers to operate 
over 5 overlapping levels, most antimalarials are likely to go through 3 steps from manufacturer to retailer 
(or 4 steps from manufacturer to end-user).  Although ACTs, and in particular artemether-lumefantrine, the 
recommended first-line treatment for uncomplicated malaria, were observed to be available in most 
wholesalers, oral AMTs and nATs were observed to have comparable levels of availability among 
wholesalers.  Furthermore, despite a policy promoting ACTs as the first-line therapy for malaria the volumes 
of ACTs sold were small, particularly when compared to sales volumes for nATs.  This may be partially 
explained by the large difference in purchase prices between ACTs and nATs, which is likely to shift demand 
toward cheaper nATs at lower levels of the supply chain and also among consumers, considering that the 
burden of malaria is disproportionately borne by the poor. [1]   
 
Another worrying observation was that, despite the presence of a ban on oral AMT products that has been 
in place since 2007, their typical sales volumes among wholesalers were sizeable and comparable to those 
for WHO-prequalified ACTs.  Wholesale percent mark-ups were observed to be consistent both across 
antimalarial categories and across dosage forms, and tended to be lower than retail-level percent mark-ups 
on antimalarials. For RDTs, their wholesale purchase prices were also low, in fact lower than the purchase 
prices for ACTs, AMTs and nATs.  They were, however, not widely available among wholesalers and their 
sales volumes were very low. 
 
When interpreting the findings of this study, it is important to consider that due to the sensitivity of some of 
the topics discussed some responses may be affected by social desirability bias, with respondents answering 
in a way that they think will meet the approval of the interviewer. Also, data for this study were collected in 
2009 and changes to the market since then are likely to have occurred, particularly due to the introduction 
of the AMFm in 2011. 
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1. Introduction & Objectives 
In Uganda, as in many low-income countries, private commercial providers play an important role in the 
treatment of malaria.  To design effective interventions for improved access to accurate diagnosis and 
effective treatment, there is a need to understand retailers' behaviour and identify the factors that influence 
their stocking and pricing decisions. Private commercial retailers are the last link in a chain of manufacturers, 
importers and wholesalers, and their supply sources are likely to have an important influence on the price 
and quality of malaria treatment that consumers can access.  However, there is limited rigorous evidence on 
the structure and operation of the distribution chain for antimalarial drugs that serves the retail sector. 
 
This study aims to address this gap and constitutes an integral part of the ACTwatch project, a multi-country 
programme of research being conducted in Uganda, Cambodia, Zambia, Nigeria, Benin, Madagascar and the 
Democratic Republic of Congo (DRC).  The overall goal of ACTwatch is to generate and disseminate evidence 
to policy makers on artemisinin-based combination therapy (ACT) availability and price in order to inform the 
development of policies designed to increase rates of access to effective malaria treatment.  Along with the 
Supply Chain Study, the ACTwatch project also includes Outlet and Household Surveys led by PSI and the 
Program for Accessible Health, Communication and Education (PACE) in Uganda. 
 
The objective of the Supply Chain component of ACTwatch is to document and analyse the supply chain for 
antimalarials and rapid diagnostic tests (RDTs) for malaria using quantitative (structured survey) and 
qualitative (in-depth interviews) methods for studying providers operating at each level of the chain.  This 
report presents the results of the structured survey of antimalarial drug wholesalers conducted in Uganda 
between February and April 2009.  In order to provide a complete description of the supply chain for 
antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices and mark-ups 
that were collected during the ACTwatch Outlet Survey by PACE Uganda/PSI between March and April 2009. 
2. Country Background  
Economic Profile 
Uganda is a landlocked country in East Africa that shares borders with the Democratic Republic of Congo, 
Kenya, Rwanda, Sudan and Tanzania.  It was one of the first Sub-Saharan African countries to embark on 
liberalization and pro-market policies in the late 1980s following several decades of political and social 
upheaval, and since then Uganda has enjoyed many years of economic growth and stability. [2] Annual 
growth in gross domestic product (GDP) has remained consistently high averaging 7% in the 1990s, but 
slowing somewhat to 5.8% in 2010 [3]; the per capita GDP in 2009 (current USD) is estimated at $483. [4]  
The Ugandan economy is heavily dependent on agriculture, which employs over 80% of the workforce; more 
than 85% of the country’s 33.4 million people live in rural areas. [3] Strong economic growth has enabled 
Uganda to make substantial progress in human development.  Most notably, it is on track to meet the 2015 
Millennium Development Goal of halving poverty, having reduced the proportion of people living in poverty 
from 57% in 1992/93 to 31% by 2005/06. [2]   
 
Pharmaceutical Sector 
The pharmaceutical sector in Uganda is regulated by the National Drug Authority (NDA), which is responsible 
for the registration of all products prior to importation and sale; regulating the marketing of 
pharmaceuticals; licensing of pharmaceutical manufacturers, importers, exporters, wholesalers and retailers; 
and for quality management and post-marketing surveillance. [5] Pharmacy practice is supervised and 
regulated by the Pharmaceutical Society of Uganda.  There are several local drug manufacturers in Uganda, 
some producing antimalarials.  However, the country still relies heavily on the importation of medicines from 
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Asia, Western countries, and some other African countries such as Kenya and South Africa.  For example, 
94% of public sector procurements are imported and only 6% are manufactured locally. [5] The medicines 
distribution system in the public sector is centralised, with  procurement pooled at the national level and 
organised through the National Medical Stores (NMS), an agency of the Ministry of Health (MOH).  The 
mission sector is also important in Uganda for medicines delivery and treatment, and procurement runs 
parallel to the public sector, with national level procurement through the Joint Medical Stores (JMS). 
 
Regarding the private pharmaceutical sector, most domestic manufacturers, importers and large wholesalers 
are located in or near the capital, Kampala.  The NDA issues different licenses each for the manufacture, 
wholesale, and retail of medicines, and permits for import and export.  Private pharmaceutical 
manufacturers must employ two registered pharmacists, while wholesale and retail pharmacies are required 
to have one registered pharmacist on staff.  As pharmacists in Uganda may be employed by a maximum of 
two separate businesses, the pharmacist may deputise responsibilities to a ‘professional auxiliary staff 
member’ (i.e. pharmacy technician, registered/enrolled nurse or midwife with pharmaceutical training) in 
their absence, two of which must be employed full-time by the business.  Drug shops, on the other hand, 
may be staffed by a pharmacy technician, registered/enrolled nurse or midwife, comprehensive nurse, 
clinical officer, public health dental assistant or anaesthetic assistant.  While drug shops are permitted to 
only retail a range of over-the-counter (OTC) medicines, known as Class C drugs, prescription-only medicines 
(POMs), the class of drugs to which antimalarials technically belong, are occasionally sold over-the-counter 
in both drug shops and retail pharmacies without a prescription. [6, 7] Despite not being authorised to 
dispense pharmaceuticals, general retail shops, such as grocery stores, dukas, and market stalls, have also 
been noted as important sources for essential medicines [6]; however, recent studies give a mixed picture 
regarding the importance of these types of retail outlets for antimalarials, with availability ranging from 0.4% 
[8] to between 8% and 44%. [9] In order to improve retail level access, ACTs were reclassified as OTC 
medicines in 2008. [10] There is no regulation of medicine prices or mark-ups. [5]  
 
Health System 
In 2007, about 6.3% of GDP was spent on health, of which just over a quarter (26.2%) was public expenditure 
accounting for 9.8% of total government expenditure in the same year. [4] Of the remaining private 
expenditure, a significant proportion is financed as out-of-pocket payments; however, the mission and NGO 
sectors both constitute important sources of health spending in Uganda. [5] Following decentralisation of 
the health sector in the 1980s, physical infrastructure is relatively well-established and operates across a 
variety of levels.  The MOH provides overall stewardship of the health sector through formulation of national 
policies, setting of quality targets, mobilisation of resources, and monitoring and evaluating of overall sector 
performance.  Services are delivered by different operational levels: community (village health team, health 
centre I), parish (health centre II), subcounty (health centre III), county (health centre IV), district (general 
hospital), regional (referral hospital) and national (referral hospital) levels.  Although 71% of the health 
infrastructure is owned by the public sector, the mission sector and private (for profit) sector also play a role, 
owning 20% and 9% of health facilities in Uganda in 2006, respectively. [5] User fees are not charged for 
services received in public facilities, and medicines can also be obtained free of charge; however, poor 
availability of medicines, increased incidence of unofficial charges, and limited geographical access to free 
public services have reduced the impact of user fee removal in Uganda. [11, 12] 
 
But despite this public sector dominance with respect to facility ownership, the barriers to access described 
above have led many to turn to the mission and private sector for health services.  Because these sectors do 
not provide services and drugs free of charge, this has implications for equity of access, particularly as there 
is no national health insurance scheme and private insurance coverage is low. [12]  
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Malaria Epidemiology and Control Strategies 
In Uganda, malaria is responsible for 30-50% of outpatient visits, 15-20% of admissions, and 9-14% of 
inpatient deaths.  Uganda ranks 6th worldwide in number of malaria cases and 3rd in number of malaria 
deaths, and the overall malaria-specific mortality is estimated to be between 70,000 and 100,000 child 
deaths annually in Uganda, a death toll that far exceeds that for HIV/AIDS. [1]  In 95% of the country, the 
malaria epidemiology is stable with perennial transmission at high levels and relatively little seasonal 
variability.  Children-under-five and pregnant women are the most vulnerable groups for infection.  The 
remaining 5% of the country consists of seasonal epidemic-prone areas in the highlands and along the 
eastern and north-eastern regions bordering Kenya and Sudan respectively.  Plasmodium falciparum (Pf) is 
the predominant parasite species. 
 
The National Malaria Control Strategy 2005/06-2009/10 focuses on the needs of the most vulnerable groups 
and includes interventions such as insecticide treated net (ITN) distribution through campaigns and 
antenatal clinics; indoor residual spraying (IRS) with a focus on low risk and epidemic-prone areas; universal 
access to ACTs and improved diagnosis; and intermittent preventive treatment (IPT) for pregnant women 
with sulphadoxine-pyrimethamine (SP).  Targets of 85% coverage for each intervention were set for 2010. 
[13]  For ACTs, the aim is to increase access through public and NGO health facilities, the community 
distribution system for medicines (home-based management of fever) and the private sector.  By 2009, 33% 
of children under five years of age and 44% of pregnant women were sleeping under ITNs, 33% of pregnant 
women were receiving at least 2 IPT doses, 6% of households had received IRS and 14% of febrile children 
were promptly treated with an ACT. [1] 
 
National Treatment Policy 
In 2004, the National Malaria Control Program (NMCP) adopted artemether-lumefantrine (AL) 20mg/120mg 
as the first-line treatment for uncomplicated malaria within the formal health sector, and artesunate plus 
amodiaquine (ASAQ) 50mg/153mg as an alternative first-line.  In April 2007, the NMCP changed its 
treatment policy for Home-Based Management of Fever for Children (HBM) from a locally manufactured SP 
+ chloroquine (CQ) product with the brand name ‘HOMAPAK’ to AL (see below for roll out plans).  Quinine is 
recommended for treatment of severe malaria and is available at health centre IV and hospitals.  According 
to national policy, consultation and treatment of uncomplicated malaria in all age groups is to be provided in 
all public health facilities and via community outreach programmes free of charge.  Oral artemisinin 
monotherapies have been banned in Uganda since 2007. 
 
The policy on diagnosis is for all adults and children over the age of five to have confirmed diagnosis through 
microscopy provided for free in public health facilities.  Although Rapid Diagnostic Tests (RDTs) are being 
introduced through pilots in facilities without microscopy, a national policy document on the use of RDTs is 
not yet finalised.  Microscopy availability is limited to health centre level III (subcounty level) and higher 
levels.  Although the policy is confirmed diagnosis, the necessary capacity is not available in many health 
centre level III facilities (the ACTwatch Outlet Survey in 2009 found that microscopy testing facilities were 
available in only 43% of public health facilities[8]), and hence, diagnosis of malaria remains largely clinical. 
 
Antimalarial Treatment Distribution and Delivery 
In 2006, Uganda began rollout of AL as first-line treatment, selecting the branded WHO-prequalified drug, 
Coartem, for distribution in public health facilities.  This was followed in 2007 with the introduction of AL at 
the community level through the HBM programme via volunteer Community Medicine Distributors (CMD), 
two of which are selected and trained per village and who receive drugs through the existing public sector 
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distribution chain.  First introduced in 10 districts in 2002 using the HOMAPAK combination noted above, the 
HBM programme was scaled up to cover all districts in Uganda by 2005. [14] Early evaluations of HBM 
conducted prior to the transition to AL showed that the intervention led to improvements in treatment 
access and adherence [15, 16], however challenges and questions have arisen since then regarding the 
sustained of availability of Coartem [10], high attrition rates of volunteer CMDs [14], and the 
appropriateness of presumptive treatment in low transmission settings in the face rising resistance and a 
policy environment that favours malaria diagnosis prior to treatment. [17] In 2009, a survey showed that 
only 18% of households knew of an active CMD in their community, and that only 9% of CMDs had ACTs. [1] 
 
A project piloting a subsidy to increase ACT access through the private sector, particularly through drug 
shops, was launched in September 2008 in the mainly rural districts of Budaka, Pallisa, Kaliro and Kamuli.  
The project, run by the Consortium for ACT Private Sector Subsidy, uses Coartem labelled with a green leaf 
distributed to retail outlets through existing private sector channels and aims for AL to be sold at a consumer 
price ranging from 200 USH to 800 USH (USD$ 0.10 to US$ 0.38) depending on the dosage.  In the first year, 
approximately 700,000 doses of AL were made available through this project, and early observations showed 
that availability of subsidised ACTs among drug shops rapidly increased, their affordability rose in the private 
sector, and drug shops seemed to charge reasonable mark-ups.  And after six months following introduction 
of the ACT subsidy, the number of children receiving treatment had increased and the augmented ACT 
uptake had eroded the market share of ineffective antimalarials, such as chloroquine. [18] Advocacy in the 
form of active participation of local government and opinion leaders, and community mobilisation including 
radio, print and point-of-sale materials were essential to ensure uptake of the subsidised ACTs. 
 
According to results from the ACTwatch Outlet Survey completed in September-October 2008, ACTs were 
most commonly available among public health facilities (over 80%) and registered pharmacies (over 55%), 
but much less so among private health facilities (less than 20%) and drug stores (less than 5%).  Non-
artemisinin therapies (nATs), on the other hand, were carried by more than 85% of all outlet types in 
Uganda. [8] In terms of treatment seeking behaviour, the ACTwatch Household Survey conducted shortly 
thereafter in early 2009 showed that only half of all children with fever were treated with an antimalarial, 
and among those treated, only 36% received an ACT; while the remaining children were most likely to 
receive an nAT.  The same study also showed that private health facilities were the most common sources of 
these treatments (42%), followed by public health facilities (24%), while 21% of children received an 
antimalarial that was already in the home; pharmacies were the source for less than 10% of antimalarials to 
treat children [19]  These results reflect the overall importance of the private sector in access to 
antimalarials in Uganda. 
 
Malaria Financing 
External funding is an important source of funding for malaria control in Uganda.  Since 2000, a sector wide 
approach (SWAp), which includes budget support, has been operational in Uganda through which many 
donors channel their aid.  An important source of financing for ACTs in the public sector is from three Global 
Fund grants (Rounds 2, 4 and 7), totalling US$ 212,100,635 over five years from 2005.  The availability of 
ACTs was somewhat affected in 2008 due to some delays in disbursements from rounds 2 and 4.  The grants 
are used in part to introduce ACTs at health facility levels and at the community level through the HBM 
policy.  In addition, Uganda has received $74.7 million from the President’s Malaria Initiative since 2006: $9.5 
million (2006), $21.5 million (2007), $21.8 million (2008) and $21.9 million (2009).  Of the grant for 2008, 
$2.5 million was allocated for case management including the procurement of ACTs for the HBM policy and 
procurement of drugs for severe malaria and pre-referral. 
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3. Methods 
3.1. Scope of the supply chain survey 
The Supply Chain structured survey was conducted amongst wholesalers who operated in the private 
commercial distribution chain that served the antimalarial drug retailers described in the 2009 ACTwatch 
Outlet Survey report. [8] The term ‘private commercial sector distribution chain’ refers to any type of 
supplier (public or private) who served private commercial outlets as well as private suppliers who served 
public and NGO outlets.  This allows any transactions between public, NGO and private commercial sectors 
to be noted.  Public suppliers of public outlets are, however, not included because much more is already 
known about the structure of the public sector chain compared to that of the private commercial sector.  
The focus is on suppliers who operate from the point where commodities leave the factory gate or port of 
entry down to those directly supplying retailers.  See Figure 3.1 for a representation of the wholesale 
supplier interactions that are captured by the Supply Chain survey. 
 
The supply chain survey explored the distribution chain for antimalarials, comprising ACTs, artemisinin 
monotherapies (AMTs) and nATs, and including all formulations (tablets, syrups, injectables, etc.), whether 
they are used for inpatient or outpatient care.  It excluded complementary products, such as drips, water 
and syringes.  It also explored the availability, sales volumes, and mark-ups on RDTs sold in the distribution 
chain under study, but excluded microscopy services.  The latter were excluded because of the wide range of 
different products used in providing microscopy services, and the problems in distinguishing those used for 
malaria diagnosis from those with other purposes. 
 
The structured survey was cross-sectional and collected data on the structure of the private commercial 
sector supply chain for antimalarial drugs, wholesaler characteristics and business practices, wholesale 
outlet licensing and inspection, wholesaler knowledge, qualifications and training; and wholesale availability, 
purchase prices and mark-ups for antimalarials and RDTs.  In order to provide a complete description of the 
supply chain for antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices 
and mark-ups that were collected during the ACTwatch Outlet Survey by PACE Uganda/PSI between March 
and April 2009. 
 
 
Figure 3.1:  Antimalarial 
wholesale supplier 
interactions captured by 
the Supply Chain Study 
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3.2. Sampling & data collection procedures 
3.2.1. Overview of sampling and data collection during the ACTwatch Outlet Survey 
For the purpose of the ACTwatch study, Uganda was divided into two strata: one stratum covering areas of 
high malaria endemicity and another stratum covering areas of prone to malaria epidemics.  In each stratum, 
19 sub-districts were randomly sampled using a probability proportional to size (PPS) approach through 
which more populated sub-districts had a higher chance of being selected.  Sub-districts were defined as the 
existing sub-counties, which typically hosts a population size of approximately 10,000 to 15,000 inhabitants; 
however, in Kampala where the subcounty populations far exceed this approximate size, a smaller sub-
division called the parish, was used as the sub-district.  In each sub-district, a census of all public and private 
outlets that had the potential to sell or distribute antimalarials was conducted and outlets that stocked 
antimalarials at the time of the survey or in the past 3 months were invited to participate in the Outlet 
Survey (OS).  In order to estimate antimalarial availability and price across different outlet types, this sample 
was supplemented by a booster sample that included all public sector outlets and registered pharmacies 
operating in the district within which the sampled sub-district was situated.  The use of a booster sample is a 
common procedure across all ACTwatch OS to ensure adequate representation of relatively rare but 
important antimalarial provider types.  All public sector outlets (e.g. health posts, health centres, hospitals) 
in the entire county which were not in the selected sub-counties/parishes and all registered pharmacies in 
the entire district that were not in the selected subcounty/parish itself that stocked antimalarials were 
identified through a census in the relevant districts.   
 
The first OS was conducted in the sampled sub-districts and booster districts by PACE Uganda/PSI between 
September and October 2008, with a second outlet survey conducted in March and April 2009.  The 
ACTwatch OS collected data on antimalarial drug availability, sales volumes and selling prices, retail outlet 
and shopkeeper characteristics (antimalarials stocked, other drugs stocked, number of staff, education, 
health-related qualifications, registration status, GPS co-ordinates) as well as other areas of importance for 
the Supply Chain Survey, including each retailer’s two top supply sources for antimalarials (name, location, 
provider type, whether they distribute, collect or both) and antimalarial wholesale purchase prices. 
 
3.2.2. Sampling and data collection procedures for the ACTwatch Supply Chain survey 
The Supply Chain survey was implemented by LSHTM from February to April 2009, with support from PACE 
Uganda, shortly after the 2009 OS.  All 38 of the OS-sampled sub-districts were used to create a list of all 
antimalarial wholesale sources mentioned by retailers as their two top antimalarial wholesale sources 
(termed the “terminal wholesalers”) during the OS administered by PACE Uganda/PSI.1  All these terminal 
wholesalers were visited and invited to participate in the Supply Chain survey.2  Wholesalers were eligible to 
participate if they met the following screening criteria: they had either an antimalarial or RDT in stock at the 
time of interview, or they reported having stocked either antimalarials or RDTs in the three months prior to 
interview.  During the interview, eligible wholesalers were also asked about their top two supply sources for 
antimalarials (termed the “intermediate-1” wholesalers).  From these data, we created a list of all 
intermediate-1 wholesalers mentioned.  All these intermediate-1 wholesalers were visited and invited to 
                                                          
1
 Supply sources for outlets that were sampled as part of the outlet survey booster sample were excluded.  
2
 There may be horizontal trading within the supply chain, for example if a terminal wholesaler purchases their antimalarial drugs 
from another wholesaler who has also been identified from the outlet survey as a terminal wholesaler.  Where these relationships 
were identified at the wholesale level the supply chain survey was not administered again to this wholesaler, though the relationship 
was noted and accounted for in the analysis.  However, in the case where horizontal trading is identified at the retail outlet level (for 
example, a retailer identifies another retailer as the source of their antimalarials), the supply chain survey was administered to the 
source of supply, even if they have already filled in the outlet survey instrument, because the questions asked were different.   
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participate in the Supply Chain survey, during which, as at previous levels, they were asked about their top 
two supply sources for antimalarials (termed the “intermediate-2” wholesalers).  This process was repeated 
until the factory gate or port of entry was reached. 
 
The Supply Chain Survey used an information sheet, a consent form, a provider questionnaire, and 
antimalarial and RDT inventory sheets.  All data collection tools were provided in English, piloted by 
members of the research team, and further revisions were made to adapt the tools to the specificities of the 
Ugandan context.  Before each interview, trained interviewers sought to speak with the most knowledgeable 
person about their antimalarial/RDT wholesale business.  They informed respondents about the study by 
providing the information sheet in English.  Interviewers stated their name, the institutions involved, aims of 
the study, nature of questions to be asked and length of the interview.  Each respondent was given the 
opportunity to ask questions at any time before, during and after the interview, and received the contact 
details of the local research coordinator.  Interviewers then invited respondents to participate in the study 
and obtained oral consent, witnessed by a member of the research team.  Interviewers emphasized that 
individual information was confidential and that no information would be passed on to regulatory 
authorities or competitors. 
 
The provider questionnaire was used for collecting data on each wholesale business’s characteristics and 
operations and on the wholesalers’ top two supply sources for antimalarials and RDTs.  Inventory sheets 
were used for collecting data for each antimalarial/RDT stocked, on brand name, generic name and strengths 
(for antimalarials), package type and size, recall of volumes sold over the week before the survey, recall of 
last purchase value and selling and purchase prices.  
 
The Supply Chain component of the ACTwatch study received ethical approval from the Research & Ethics 
Committee of the Makerere University Faculty of Medicine and the LSHTM ethics review committee. 
 
3.3. Data analysis 
3.3.1. Classification of outlets 
A challenge in the analysis of wholesalers is their classification into sub-groups, as in practice many operate 
at several levels of the distribution chain.  We have taken 2 approaches:  
 To describe the structure of the chain, wholesalers were classified into mutually-exclusive categories 
(MECs) defined by the levels they supplied.  For example, wholesalers supplying retailers only, 
wholesalers supplying retailers and terminal wholesalers only, and wholesalers supplying intermediate 
and terminal wholesalers only. 
 For analytical purposes, wholesalers were grouped into 2 broader and overlapping categories: one 
including wholesalers supplying retailers and one for wholesalers supplying wholesalers.  Some 
wholesalers may therefore be included in both analytical categories.  This second approach for 
classifying wholesalers addresses the issues of individual MECs including very few wholesalers.  
Furthermore, this approach reflects the actual operations of the distribution chain. 
In order to get a complete picture of the distribution chain for antimalarial drugs, data relevant to the retail 
level are also presented for 5 mutually exclusive categories of retailers:  pharmacies, private health facilities, 
drug stores, other private outlet types (e.g. grocery stores, general stores, etc.), and public health facilities.  
See appendix 6.2 for descriptions of the type of retailers included in these categories. 
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3.3.2. Calculation of sales volumes 
Antimalarial volumes and price data are reported for 5 dosage forms, namely tablets, oral liquids, 
injectables3, suppositories and granules, and 3 antimalarial categories4 namely artemisinin-based 
combination therapy (ACT), artemisinin monotherapies (AMT) and non-artemisinin therapies (nAT).  ACTs 
were further sub-divided into WHO-prequalified ACT and non-WHO-prequalified ACT. 
 
Antimalarial volumes were calculated on the basis of an adult equivalent treatment dose (AETD).  An AETD 
was defined as the number of milligrams (mg) of an antimalarial drug needed to treat a 60 kg adult (refer to 
Appendix 6.3 for data used during calculation of AETDs).  The number of mg/kg used to calculate one AETD 
was defined as what was, at the time of the study, recommended for a particular drug combination in the 
treatment guidelines for uncomplicated malaria in areas of low drug resistance issued by the WHO.  Where 
WHO treatment guidelines did not exist, AETDs were based on product manufacturers’ treatment guidelines.  
In the case of ACTs as the treatment consists of two or more active antimalarial ingredients packaged 
together (either co-formulated or co-blistered), the strength of the artemisinin-based component was used 
as the principal ingredient for the AETD calculations.  Information collected on both the medicine strength 
and unit size, as listed on the product packaging, was then used to calculate the number of AETDs contained 
in each unit.  The median number of antimalarial doses reported to have been sold during the week 
preceding the survey was estimated for each antimalarial category for each wholesaler category.  Estimates 
were calculated by first summing the number of AETDs sold for the different antimalarial categories at each 
wholesale outlet and then by taking the median across the wholesaler category.  Similar estimates were 
made for RDT sales volumes in each wholesaler category. 
 
For wholesale outlets that stocked antimalarials/RDTs and for which some or all sales volumes were missing, 
missing values were imputed using the STATA 11 command mi impute pmm5.  For wholesale outlets with no 
antimalarials of a given category in stock at the time of the survey, sales volumes over the past week were 
assumed to be null.  For wholesale outlets without information about the type of antimalarials stocked 
(because of refusals to participate in the study or to provide information on the type of antimalarials stocked 
or because of interrupted interviews), sales volumes were treated as missing.  In the case of an outlet not 
stocking antimalarials, sales volumes were set to zero. 
 
3.3.3. Calculation of purchase prices and mark-ups 
Wholesale purchase prices and mark ups were calculated using data collected during the ACTwatch Supply 
Chain Survey.  Because it is common for wholesalers to vary their prices with the volumes they sell, 
minimum, mid-point and maximum mark-ups were calculated using data on maximum and minimum selling 
price charged for one unit by wholesalers.  The wholesale maximum percentage mark-up was calculated as 
the difference between the highest wholesale selling price (that is the price of the minimum volume sold 
wholesale) and the wholesale purchase price, divided by the wholesale purchase price.  The wholesale 
minimum mark-up was calculated as the difference between lowest wholesale selling price (that is the 
minimum price charged for wholesale sales) and wholesale purchase price, divided by wholesale purchase 
price.  The wholesale percent mid mark-up was calculated as:  
                                                          
3
 Liquid and powder injectables form a single category. 
4
 Antimalarial drugs intended for prophylaxis and drug combinations not used to treat malaria but that contain an ingredient with 
antimalarial action were excluded from analysis.  
5
 A technique used for imputing missing values of one continuous variable whose distribution is skewed.  Missing values (e.g. in the 
case of an outlet stocking antimalarials and with the antimalarial type identified in the audit sheet but for which sales volume data 
were missing) were imputed using covariates related to provider/outlet and product characteristics.  Five imputations were 
conducted and their mean imputed to the missing values.   
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[[[(highest selling price)+(lowest selling price)]/2]- (wholesale purchase price)]/(wholesale purchase price) 
 
Retail purchase prices and mark-ups were calculated using price data collected during the 2009 ACTwatch 
OS.  When calculating summary estimates for purchase prices and mark-ups, there was a need to weight 
outlet survey data to allow for (a) the difference in sampling probabilities due to variation in the size of 
strata, (b) the oversampling for the booster, and (c) the sampling strategy which involves a census of retail 
outlets in the sub-districts of varying size selected using PPS. Stratum-specific weights were calculated for 
each sub-district sampled in the stratum (endemic vs. epidemic-prone areas).  Appendix 6.4 provides a 
detailed description of the calculations performed and weights used. 
 
Retail percentage mark-ups were calculated for each product as the difference between selling price and 
purchase price, divided by purchase price.  For both retail and wholesale observations, absolute mark-ups 
per AETD were calculated for each product as selling price minus purchase price.  Data were collected in 
local currencies and converted to their US$ equivalent using the average interbank rate during the data 
collection period.6 
 
3.3.4. Summary measures 
Indicators are reported using median and inter-quartile range (IQR), which are relevant for describing 
distributions likely to be skewed.  Given that for analytical purposes, wholesalers were classified into 
overlapping categories (i.e. wholesalers supplying retailers and wholesalers supplying wholesalers), it was 
not possible to conduct statistical tests of difference between the 2 groups.  
4. Results 
4.1. Overview of the sample 
A total of 295 supply sources were listed by retailers sampled in the 38 selected OS sub-districts, of which 
150 (50.8%) were obvious duplicates, two (0.7%) were listed with a general location but without a supplier 
name, and one private sector retailer listed the government agency, National Medical Stores, as one of its 
top suppliers of antimalarials.  For the remaining 142 supply sources, other uncertainties around supplier 
business names or locations were clarified by calling suppliers, and in the absence of contact numbers, 
advice on location was sought from local informants, including PACE staff members and data collectors who 
had participated in the OS data collection.  This process identified 28 (9.5%) additional duplicates, leaving a 
total of 114 suppliers to form the sample of terminal wholesalers.  Out of the 114 terminal level wholesalers, 
one was ineligible to participate, two could not be located and four had closed down.  Among those eligible 
to participate, one refused and two stopped the interview before completing all sections of the provider 
questionnaire or the inventory of antimalarials, leaving 104 terminal wholesalers with completed interviews. 
 
All 104 terminal wholesalers who were successfully interviewed were asked about their top two supply 
sources for antimalarials.  From a total of 180 wholesaler mentions, six referred to foreign manufacturers 
(which are beyond the scope of this study), and the remaining 174 wholesaler mentions referred to 55 
unique wholesale businesses, called intermediate-1 wholesalers as they supplied terminal wholesalers, three 
                                                          
6
 Outlet Survey data collection took place between 16 March and 7 April 2009 and an average exchange rate of 1 US$ to 2113.53 
Uganda Shillings during the data collection period was used for the calculation of retail absolute mark-ups.  Supply Chain Survey data 
collection took place between 13 February and 6 April 2009 and an average exchange rate of 1 US$ to 2049.16 Uganda Shillings 
during the data collection period was used for the calculation of wholesale absolute mark-ups.  Historical exchange rates averaged 
over the specified periods were obtained from http://www.oanda.com/currency/historical-rates.  
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of which referred to local manufacturers (which are also beyond the scope of this study).  Of these 52 eligible 
intermediate-1 wholesalers, 27 had already been identified at the terminal level (as they also supplied 
retailers included in the Outlet Survey sample directly), of which two had closed down. As such, an interview 
was not re-administered to these 27 wholesalers.  Of the remaining 25 intermediate-1 wholesalers, 
interviews were successfully administered to 23 and two refused.  From the 48 intermediate-1 wholesalers 
(the 25 interviewed at terminal level and 23 were newly interviewed), we obtained 84 total mentions for 
intermediate-2 wholesalers of which 17 were foreign manufacturers, and the remaining 67 mentions 
referred to 27 unique wholesalers.  Three of these were local manufacturers, leaving 24 in total, 23 of which 
had been identified at previous levels (22 interviews were completed and 1 refused).  The one remaining 
wholesaler newly identified at this level refused to participate.  These 22 intermediate-2 wholesalers 
produced a total of 36 mentions for intermediate-3 wholesalers.  A third of these were foreign 
manufacturers, and the remaining 24 mentions referred to 13 unique wholesalers.  Two of these were local 
manufacturers, and of the 11 remaining intermediate-3 wholesalers, all 11 had already been identified at 
previous levels (10 interviews completed, 1 refusal).  Therefore, no new interviews were conducted at this 
level.  A total of 17 mentions of intermediate-4 wholesalers were gathered and eight of these were foreign 
manufacturers.  Of the remaining nine mentions, six were unique businesses, one of which was a local 
manufacturer.  All five remaining wholesalers had already been identified and successfully interviewed at 
previous levels.  As each of these intermediate-4 wholesalers mentioned manufacturers as their two top 
antimalarial suppliers, the top of the chain was deemed to have been reached with a total of 142 
wholesalers that sold antimalarials identified, with whom 127 interviews were completed, two interviews 
were partially completed, four refused interview, one was not eligible because it did not stock antimalarials 
or RDTs at the time of interview or in the preceding three months, two could not be located, and six had 
closed their business permanently. (Table 4.1) 
 
 
Table 4.1: Overview of the wholesalers sampled and interviewed 
Levels of  
operation 
Initial 
Sample 
Size 
Number 
identified at 
previous 
level(s) 
Number of 
refusals
1
 
Number of 
duplicates
2
 
Number 
not 
eligible
3
 
Number not 
interviewed 
for other 
reasons
4
 
Number 
not found 
Number of 
interviews 
conducted
5 
Total - - 4 28 1 6 2 129 
Terminal 142 - 1 28 1 4 2 106 
Intermediate-1 52 27 2 0 0 2 0 23 
Intermediate-2 24 23 2 0 0 0 0 0 
Intermediate-3 11 11 1 0 0 0 0 0 
Intermediate-4
6
 5 5 0 0 0 0 0 0 
1: One refusal each at intermediate-2 and intermediate-3 level occurred at previous levels.  2: Wholesalers included in the initial sample 
and found to be duplicates during data collection.  3: Outlets not stocking antimalarials or RDTs at the time of the interview or in the 
preceding 3 months.  4: Wholesalers mentioned by respondents at a previous level had closed their business. 5: Partial interviews were 
conducted with 2 wholesalers at terminal level (i.e. 2 partial and 104 completed interviews). 6: This is the top of the chain, defined as the 
level at which wholesalers who were reported to supply intermediate-3 wholesalers mentioned only manufacturers as top supply sources 
for antimalarials. In the ACTwatch protocol, this level was referred to as the primary level where wholesalers who receive supplies directly 
from manufacturers operated. 
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4.2. Structure of the private commercial sector distribution chain for antimalarials 
 The observed maximum number of steps from manufacturers’ factory gate to retail outlet is six: 
manufacturer  intermediate-4 wholesaler  intermediate-3 wholesaler  intermediate-2 wholesaler 
 intermediate-1 wholesaler  terminal wholesaler  retailer. 
 Among all wholesalers surveyed, regardless of supply chain level, 81.4% were observed to sell directly to 
retailers, 62.1% sold to retailers only, while 37.9% of all wholesalers also supplied other wholesalers (i.e. 
horizontal trading). 
 While 41.2% of all antimalarial wholesalers were located in Kampala, a much greater proportion of the 
larger wholesalers supplying other wholesalers were located in Kampala (65.3%) than wholesalers 
supplying retailers (33.9%) 
 Of all the wholesalers that stocked antimalarials, one-fifth constituted part of one of the several 
observed vertically integrated wholesale supply chains, where importers or large pharmaceutical 
wholesalers typically based in Kampala also owned and/or operated one or more subsidiary wholesalers 
in regional commercial centres in different parts of the country. In most cases, these subsidiary 
wholesalers were supplied exclusively by the ‘parent’ wholesaler located in Kampala.  
 In terms of transactions between the public and private sector, no wholesalers reported a public source 
as one of their two top suppliers of antimalarials; however, one private retailer reported a public source 
(the National Medical Stores) as one of their two top suppliers of antimalarials (although this is likely 
erroneous), and 3 public facilities surveyed at outlet level mentioned a private sector source as one of 
their two top antimalarial suppliers. 
 The structure of the private commercial sector distribution chain for antimalarials in Uganda is depicted 
in Figures 4.2.1 and 4.2.2.  In Figure 4.2.1, each red dot represents a mutually exclusive group of 
wholesalers that are defined by the specific supply chain levels that each wholesaler group serves (these 
interactions are shown by the array of arrows emanating from each dot).  The relative size of each group 
is shown in the attached percentage.  The dashed line from manufacturer to retailer indicates that a few 
retailers purchased antimalarials directly from manufacturers, although this was rare (0.3% of all 
suppliers mentioned by retailers were local drug manufacturers). Figure 4.2.2 depicts how wholesalers 
have been grouped into the overlapping analytical categories used throughout this report, while Table 
4.2 shows how these analytical categories have been derived from the mutually exclusive categories 
depicted in Figure 4.2.1. 
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Table 4.2: Defining analytical categories from mutually exclusive wholesaler categories 
WHOLESALER 
CATEGORIES 
Total 
MUTUALLY EXCLUSIVE CATEGORIES ANALYTICAL CATEGORIES 
Supplies 
int 1 
Supplies 
int 1 & 
terminal 
Supplies 
int 1, 
terminal 
& retailer 
Supplies 
retailer 
Supplies 
terminal 
Supplies 
terminal 
& retailer 
Supplies 
int 2, int 1 
& terminal 
Supplies 
int 2, int 1, 
terminal & 
retailer 
Supplies 
int 3, int 1 
& terminal 
Supplies 
int 3, int 2, 
int 1 & 
terminal 
Supply 
Retailers 
Supply 
Wholesalers 
% of WS 100% 0.7% 2.1% 5.7% 62.1% 9.3% 11.4% 2.9% 2.1% 0.7% 2.9% 81.4% 37.9% 
(N) (140) (1) (3) (8) (87) (13) (16) (4) (3) (1) (4) (114) (53) 
 
WS: wholesaler, int: intermediate wholesaler 
Figure 4.2.1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive 
wholesaler category 
 
 
WS: wholesaler;  INT: intermediate 
Figure 4.2.2: Representation of the 
antimalarial distribution chain showing the 
overlap between wholesaler categories used 
for analysis 
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4.3. Wholesaler characteristics and business practices 
4.3.1. Years in operation, outlet size and range of products sold 
 Wholesale businesses were of a relatively small size (median of six workers) and had been in operation 
for a median of eight years.  Wholesalers supplying other wholesalers tended to be slightly larger and 
have been in business for longer (median of eight workers and nine years in operation) than wholesalers 
supplying retailers (median of five workers and six years in operation).  
 More than half of all wholesalers (56.6%) sold other products alongside pharmaceuticals.  The most 
common consumer goods stocked were toiletries (45.7% of all wholesalers), while less than 5% of all 
wholesalers sold household goods, mobile phone credit, cigarettes or food. 
 
Table 4.3.1: Years in operation, outlet size and range of products sold 
 WHOLESALER CATEGORIES 
CHARACTERISTICS 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Years in operation Median 8 9 6 
 IQR 3-11 5-13 3-11 
 (N) (123) (47) (99) 
Number of people working at outlet Median 6 8 5 
 IQR 4-9 5-11 4-8 
 (N) (128) (48) (105) 
Sells other products in addition to 
pharmaceuticals1 
% 56.6 53.1 54.3 
(N) (129) (49) (105) 
IQR: Inter-quartile Range; 1: other products included toiletries, mobile air time, cigarettes, prepared food, groceries and/or 
household goods 
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4.3.2. Wholesalers’ customers, delivery activities and credit facilities 
Wholesalers mentioned a broad range antimalarial customer types in both private and public sectors.  The 
most frequently mentioned customers were pharmacies and drug stores (92.3%); and private clinics, health 
centres and dispensaries (92.3%), other drug wholesalers (84.5%) and retail customers (89.2%). 
Customer types 
 Three wholesalers reported selling antimalarials to government ministries and agencies, such as the 
Ministry of Defence, the Ministry of Internal Affairs, and the NMS – an agency of the Ministry of Health 
that manages public sector procurement; one wholesaler reported selling antimalarials to the mission 
sector procurement agency, the JMS, and also to the national Red Cross; schools were also mentioned as 
customers by three other wholesalers. 
 A higher proportion of wholesalers that supplied retailers (92.4%) reported selling antimalarials directly 
to retail customers compared to those wholesalers supplying other wholesalers (77.6%). 
 Conversely, when compared to wholesalers supplying retailers, a higher proportion of wholesalers that 
supplied other wholesalers reported selling to private hospitals (79.8% vs. 93.9%), public hospitals 
(67.3% vs. 81.6%), private clinics, health centres and dispensaries (90.5% vs. 100%), public clinics, health 
centres and dispensaries (77.1% vs. 87.8%), and to customers in other countries (26.9% vs. 41.7%). 
 Nearly a third of all wholesalers interviewed (30.5%) reported selling antimalarials to customers in other 
countries; the most common countries were Sudan (51.3% of wholesalers), DRC (51.3%), Tanzania 
(23.1%), Kenya (20.5%), Rwanda (20.5%), Burundi (5.1%) and Somalia (2.5%).  
Business practices 
 Nearly half (47.9%) of wholesalers supplying other wholesalers reported importing antimalarials, while 
16.4% of wholesalers supplying retailers imported antimalarials; and among wholesalers who imported, 
43.3% did not sell antimalarials directly to terminal wholesalers. 
 10.2% of all wholesalers identified a manufacturer as one of their two top antimalarial suppliers; 
however, the proportion was higher among wholesalers supplying other wholesalers compared to those 
supplying retailers (22.9% vs. 3.9%) 
 A third (32.0%) of all wholesalers reported delivering antimalarials to their customers; but half of the 
wholesalers supplying other wholesalers delivered compared to only a quarter (26.0%) among those 
supplying retailers. 
 Three quarters of all wholesalers interviewed had offered credit to customers in the past three months, 
offering a median of 30 days credit (IQR 14-30).  Although a greater proportion of wholesalers operating 
at the higher levels of the supply chain (i.e. wholesalers supplying wholesalers) reported providing credit 
(87.8% vs. 71.2%), the credit terms did not vary widely across supply chain levels. 
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Table 4.3.2: Wholesalers’ Customers, Delivery Activities and Credit facilities 
  
 WHOLESALER CATEGORIES 
ANTIMALARIAL CUSTOMER TYPES 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Retail Customers (e.g. patients, care-takers) % 89.2 77.6 92.4 
 (N) (129) (49) (105) 
Retail Outlets 
Pharmacies or drug stores % 92.3 95.9 92.4 
 (N) (129) (49) (105) 
General retailers (grocery stores, kiosks, etc.) % 73.21 70.8 73.8 
 (N) (127) (48) (103) 
Public clinics, health centres or dispensaries % 79.1 87.8 77.1 
 (N) (129) (49) (105) 
Private clinics, health centres or dispensaries % 92.3 100.0 90.5 
 (N) (129) (49) (105) 
Public hospitals % 69.5 81.6 67.3 
 (N) (128) (49) (104) 
Private hospitals % 81.3 93.9 79.8 
 (N) (128) (49) (104) 
Wholesale Outlets 
Drug wholesalers % 84.5 98.02 81.9 
 (N) (129) (49) (105) 
General wholesalers % 62.8 67.4 62.9 
 (N) (129) (49) (105) 
Customers in Other Countries % 30.5 41.7 26.9 
 (N) (128) (48) (104) 
BUSINESS PRACTICES 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Import antimalarial drugs % 23.4 47.9 16.4 
(N) (128) (48) (104) 
Buy directly from antimalarial manufacturers 
(as one of two top antimalarial suppliers) 
% 10.2 22.9 3.9 
(N) (127) (48) (104) 
Deliver antimalarials to customers % 32.0 50.0 26.0 
(N) (128) (48) (104) 
Provided credit to customers in the past 3 
months 
% 75.0 87.8 71.2 
(N) (128) (49) (104) 
Most common terms of credit offered in the 
past 3 months (number of days) 
Median 30 30 30 
IQR 14-30 30-30 14-30 
(N) (93) (43) (71) 
1:  Some wholesalers interviewed may have understood the question asked to mean customers for ‘any medicines’ and not specifically 
antimalarials, or perhaps customers that buy ‘any medicines for the management of malaria’, which may include antipyretics, 
vitamins, etc. that are commonly sold by general retailers.  2: One of the 49 wholesalers in this category reported that they did not 
supply drug wholesalers; however, during the supply chain survey, a wholesale respondent identified this particular wholesaler as one 
of their top two supply sources for antimalarials. To remain consistent across indicators, we have chosen to report this indicator as 
98.0% rather than 100.0% based on the information reported by respondents. 
 24 
4.4. Licensing & inspection 
A high proportion of wholesalers were observed to have a license from the National Drug Authority while 
possession of retail licenses and import licenses was lower.  Nearly all (99.2%) wholesalers interviewed 
reported that they had been visited by a pharmaceutical inspector in the past year. 
 Among all wholesalers interviewed, 82.8% reported having a wholesale pharmacy license. 
 Two-thirds (66.4%) of all wholesalers interviewed reported having a retail pharmacy license, although a 
higher proportion of wholesalers supplying retailers (71.4%) reported having a retail license compared to 
wholesalers supplying other wholesalers (54.2%); 8 wholesalers also reported having a Class C license 
from the National Drug Authority, which is typically obtained by drug shops and permits the retail of 
selected over-the-counter medicines (however, not antimalarials). 
 Any up-to-date license from the National Drug Authority (wholesale or retail) was observed in 82.8% of 
all wholesalers interviewed. A higher proportion of wholesalers operating at higher levels of the supply 
chain (i.e. wholesalers supplying wholesalers) were observed to have an up-to-date license compared to 
wholesalers supplying retailers (91.7% vs. 81.0%). 
 Possession of a pharmacy import license was reported by more wholesalers operating at higher levels of 
the supply chain (i.e. wholesalers supplying wholesalers) compared to those supplying retailers (40.4% 
vs. 16.4%); these figures were similar to the number of wholesalers who reported importing 
antimalarials: 47.9% of wholesalers supplying wholesalers vs. 16.4% of wholesalers supplying retailers. 
 However, the percentage of wholesalers that reported selling antimalarials directly to retail customers 
(89.2%) was higher than the percentage of wholesalers that reported having the required license to do 
so (66.4%). 
 
Table 4.4: Licensing & Inspection 
 WHOLESALER CATEGORIES 
REGISTRATION STATUS 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Reported having a license allowing wholesale 
of pharmaceuticals 
% 82.8 95.8 81.0 
(N) (128) (48) (105) 
Reported having a license allowing retail of 
pharmaceuticals 
% 66.4 54.2 71.4 
(N) (128) (48) (105) 
Reported having an import license % 20.6 40.4 16.4 
 (N) (126) (47) (104) 
Reported having a exporter license % 7.1 12.7 7.7 
 (N) (127) (47) (104) 
Reported having a manufacturer license % 1.6 4.2 1.9 
 (N) (128) (48) (105) 
Any up-to-date license from the National Drug 
Authority was observed1 
% 82.0 91.7 81.0 
(N) (128) (48) (105) 
An up-to-date wholesaler license from the 
National Drug Authority was observed 
% 63.3 79.2 61.0 
(N) (128) (48) (105) 
An general business or trading license was 
observed2 
% 75.8 70.8 79.1 
(N) (128) (48) (105) 
Reported they had been visited by a 
pharmaceutical inspector in the past year 
% 99.2 100.0 99.0 
(N) (123) (48) (100) 
1: This license may be either a retail or wholesale pharmacy license, but not a Class C license intended solely for the retail of specific OTC drugs, not 
including antimalarials; this includes wholesalers who had a recently valid pharmacy license (i.e. Expired Nov or Dec 2008) as licences for 2009 were 
still being processed by the authorities at the time of  data collection; 2: The trading license is a general business license required for all companies; 
only a date of issue is listed on the certificate and no expiry date. 
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4.5. Knowledge, qualifications and training 
All wholesalers surveyed employed at least one staff member with health-related qualifications and most 
correctly identified the government-recommended first line treatment for uncomplicated malaria. However, 
fewer wholesalers believed ACTs to be the most effective antimalarial treatment. 
 Most wholesalers (86.7%) were able to correctly identify AL as the government recommended first-line 
treatment for uncomplicated Pf malaria; however, a greater proportion of wholesalers operating at 
higher levels of the supply chain were able to do so compared to those supplying retailers (93.8% vs. 
83.8%). 
 Despite this, the percentage of wholesalers identifying an ACT as the most effective medication for 
treating uncomplicated malaria was somewhat lower (40.2% for children and 52.8% for adults).  AL was 
most commonly mentioned as the most effective antimalarial among all wholesalers (34.7% for children 
and 39.4% for adults); while 18.9% of wholesalers mentioned an AMT, artemether, for the treatment of 
malaria in both adults and children, and was the second most commonly mentioned ‘most effective’ 
antimalarial.  Among all wholesalers, the third and fourth most commonly mentioned as ‘most effective’ 
for the treatment of malaria in children were SP (15.0%) and CQ (13.4%). 
 All wholesalers reported employing staff with health qualifications.  The most commonly reported health 
qualifications were nurses/midwives (89.8%), followed by pharmacists (88.3%), and pharmacy assistants 
(24.2%). 
 The percentage of wholesalers who indicated that staff had participated in in-service training related to 
malaria treatment in the past two years was low (15.0% of all wholesalers interviewed). 
Table 4.5: Wholesalers’ knowledge, qualifications and training 
 WHOLESALER CATEGORIES 
HEALTH QUALIFICATIONS, TRAINING AND KNOWLEDGE 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Employ a member of staff with health 
qualifications1 
% 100.0 100.0 100.0 
(N) (128) (48) (105) 
Employ staff who participated in in-service training 
related to malaria treatment in the past 2 years 
% 15.0 14.6 14.4 
(N) (127) (48) (104) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in adults 
% 52.8 62.5 48.1 
(N) (127) (48) (104) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in children 
% 40.2 50.0 37.5 
(N) (127) (48) (104) 
Correctly identify the government recommended 
first line treatment for uncomplicated Pf malaria 
% 86.7 93.8 83.8 
(N) (128) (48) (105) 
1: Health qualifications included pharmacist, pharmacy technician, pharmacy assistant, medical doctor, nurse, 
midwife, clinical officer, nursing assistant  
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4.6. Storage of antimalarial drugs 
Most wholesalers were observed to follow good medicines storage practices, including storage in dry areas 
out of direct sunlight and off the floor. 
 All wholesalers were observed to store antimalarials in a dry area; almost all of whom were observed to 
keep them out of direct sunlight (97.6%) or off the floor (94.4%). 
 92.1% of all wholesalers met each of the specified conditions for good storage of antimalarials (in a dry 
area, out of direct sunlight and off the floor); however, more wholesalers supplying other wholesalers 
were observed to comply with all conditions compared to those supplying retailers (95.7% vs. 91.3%). 
 
Table 4.6: Wholesalers’ storage practices 
 WHOLESALER CATEGORIES 
STORAGE 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Store antimalarials in a dry area % 100.0 100.0 100.0 
(N) (126) (47) (103) 
Store antimalarials out of direct sunlight % 97.6 97.9 98.1 
(N) (126) (47) (103) 
Store antimalarials off the floor % 94.4 97.9 93.2 
(N) (126) (47) (103) 
Store antimalarials in a dry area, out of direct 
sunlight & off the floor 
% 92.1 95.7 91.3 
(N) (126) (47) (103) 
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4.7. Availability of antimalarials & RDTs 
More than three-quarters of all wholesalers surveyed (88.3%) had an ACT in stock at the time of interview, 
and a similar proportion (83.3%) of all wholesalers reported having had at least one ACT in stock throughout 
the three month period prior to interview. Oral AMTs were stocked by a similar proportion of wholesalers 
(75.8%), while less than a fifth (18.0%) stock RDTs. 
 Nearly all wholesalers surveyed (99.2%) had at least one antimalarial in stock at the time of interview.  
 A higher proportion of wholesalers had non-WHO-prequalified ACTs in stock (75.0%) than WHO-
prequalified ACTs (52.3%). 
 AL, the recommended first-line treatment for uncomplicated Pf malaria, was stocked by 74.0% of all 
wholesalers; however, it was only the third most frequently observed antimalarial, accounting for 13.0% 
of all antimalarial products stocked by wholesalers and 53.9% of all ACTs stocked; of all the AL products 
observed, 45.4% were WHO-prequalified brands. 
 The second most frequently observed ACT stocked by wholesalers after AL was dihydroartemisinin 
piperaquine, accounting for 5.3% of all antimalarial products stocked by wholesalers and 22.3% of all 
ACTs stocked. 
 Oral AMTs were stocked by 75.8% of all wholesalers, and non-oral AMTs by 51.6% of all wholesalers. 
 The two most frequently observed antimalarials were artemether (an AMT), followed by quinine (19.2% 
and 18.4% of all products stocked by wholesalers, respectively).  SP accounted for 10.6% of all products 
stocked by wholesalers, and chloroquine, 9.1%.  More than half (55%) of the artemether products, 72% 
of the quinine products and virtually all of the SP (98%) and chloroquine (97%) products stocked by 
wholesalers were oral formulations, with the remainder in injectable dosage form. 
 RDTs were stocked by less than a fifth (18.0%) of all wholesalers at the time of interview; however, a 
higher proportion of wholesalers operating at higher levels of the supply chain (i.e. wholesalers 
supplying wholesalers) were observed to have RDTs in stock compared to wholesalers supplying retailers 
(32.0% vs. 17.1%). 
Table 4.7: Antimalarial & RDT availability 
 WHOLESALER CATEGORIES 
AVAILABILITY 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Had antimalarials in stock  % 99.2 96.0 99.0 
(N) (128) (50) (105) 
Had ACT in stock  % 88.3 92.0 86.7 
(N) (128) (50) (105) 
Always had at least one ACT in stock over the past 
3 months 
% 83.3 87.5 82.5 
(N) (126) (48) (103) 
Had WHO-prequalified ACT in stock % 52.3 50.0 54.3 
(N) (128) (50) (105) 
Had non-WHO-prequalified ACT in stock % 75.0 80.0 74.3 
(N) (128) (50) (105) 
Had oral AMT in stock % 75.8 72.0 79.0 
(N) (128) (50) (105) 
Had non-oral AMT in stock % 51.6 50.0 53.3 
(N) (128) (50) (105) 
Had nAT in stock % 89.1 78.0 92.4 
(N) (128) (50) (105) 
Had RDT in stock  % 18.0 32.0 17.1 
(N) (128) (50) (105) 
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4.8. Sales volumes of antimalarials and RDTs 
Typical sales volumes were greatest for non-artemisinin therapies, followed by ACTs, and smallest for AMT. 
AMT sales volumes were dominated by tablets. More than a third of all wholesalers reported SP as their top 
selling antimalarial, while the government recommended first-line treatment, AL, was the top selling 
antimalarial for only a tenth of all wholesalers. 
Among all wholesalers (n=127; Table 4.8.1) 
 The median number of adult equivalent treatment doses (AETDs) sold the week preceding the survey 
was 22.0 (IQR 4.8-94.4) for ACTs and 15.0 (IQR 2.3-34.8) for AMT, but much higher for nATs: 304.9 (IQR 
52.1-1523.7).   
 Most wholesalers (83.6%) reported selling an ACT during the week preceding the survey; this figure was 
79.7% for AMTs and 87.5% for nATs.    
 Across the different antimalarial drug categories, more AETDs were sold as tablets than any other 
dosage form, particularly for AMTs where the median sales volume for tablets was 7.7 AETDs (IQR 0.0-
18.8) and 0.0 AETDs for oral liquid and injectable dosage forms. However, relatively high median 
volumes of oral liquid nATs were sold by wholesalers.  The volumes of granule and suppository dosage 
forms sold were very low:  median sales volumes among all wholesalers stocking any antimalarial across 
all antimalarial categories were 0 (IQR 0-0).  See Appendix 6.1 for additional tables on sales volumes of 
suppository and granule dosage forms. 
 Only 10.2% reported the recommended first line treatment for uncomplicated malaria, AL, to be their 
top selling antimalarial, while higher proportions of wholesalers reported SP (36.2%), CQ (18.1%) and 
quinine (11.8%) to be their top selling antimalarial.7 
 However, compared to wholesalers supplying retailers, a higher proportion of wholesalers supplying 
other wholesalers (18.8%) reported AL to be their top selling antimalarial drug, second only to SP, the 
top-selling antimalarial of 22.9% of these wholesalers.  Following behind was chloroquine (14.6%) and an 
AMT, artemether, reported by 12.5% of wholesalers supplying wholesalers as their top selling 
antimalarial. 
Among wholesalers stocking the corresponding product category (Table 4.8.2) 
 Considering only wholesalers who stocked ACT (n=113), the median ACT sales volumes sold the week 
preceding the survey was 30.0 (IQR 10.0-99.9). The median sales volume of WHO-prequalified ACTs 
among the 108 wholesalers stocking them (10.0 AETDs, IQR 5.0-40.0) was about half the observed sales 
volume of non-WHO-prequalified ACTs (18.3 AETDs, IQR 5.4-85.8) among the 96 wholesalers who 
stocked them. Among wholesalers supplying other wholesalers, non-WHO-prequalified ACTs were even 
more dominant (median of 50.7 AETDs, n=40; compared with 20.0 for WHO-prequalified ACTs, n=25).  
 Considering only wholesalers who stocked nAT (n=114), the median nAT sales volumes in the past week 
were 372.7 AETDs (IQR 125.0-2092.8).  
 Of wholesalers stocking AMT (n=103), their median AMT sales volumes were 20.5 AETDs (IQR 10.1-62.5).  
AMT tablets were stocked by 92 wholesaler who sold a median volume of 13.8 AETDs (IQR 6.3-26.9) the 
week preceding the survey; AMT injectables were stocked by 65 wholesaler who sold a median volume 
of 8.3 AETDs (IQR 2.4-30.0); and only 29 wholesalers stocked AMT oral liquid products and sold a median 
volume of 1.6 AETDs (IQR 0.6-6.3).  
 RDTs were not commonly stocked by wholesalers. Among those who did stock RDTs (n=22), the volume 
of tests sold varied widely both within and across supply chain levels.  Among those who stocked RDTs, 
the median number of tests sold during the week preceding the survey was 15 (IQR 2.5-50.5) among 
wholesalers supplying wholesalers, while wholesalers supplying retailers sold a median 8.5 tests (IQR 0-
50).  
                                                          
7
The analysis of the top selling antimalarials used sales volumes data collected for each antimalarial in stock at the time of the 
survey:  in each outlet and for each antimalarial stocked, wholesalers were asked to recall the quantity they had sold during the week 
preceding the survey 
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Table 4.8.1: Median number of AETDs & RDTs sold during the week preceding the survey (all wholesalers) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
N=127
3
 N=48
 
N=104 
All ACT All Median 22.0 58.8 18.9 
IQR 4.8-94.4 15.8-343.6 4.0-57.1 
Tablet Median 21.9 56.4 18.1 
IQR 4.0-86.7 14.3-295.1 3.7-56.2 
Oral liquid Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-2.3 0.0-0.0 
WHO-prequalified 
ACT 
All products 
were tablets 
Median 2.0 1.0 2.0 
IQR 0.0-10.0 0.0-20.0 0.0-10.0 
Non-WHO-
prequalified ACT 
All Median 9.8 30.9 8.9 
IQR 0.0-46.5 3.3-216.0 0.0-37.7 
Tablet Median 9.4 24.5 8.7 
IQR 0.0-44.4 1.0-194.4 0.0-36.8 
Oral liquid Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-2.3 0.0-0.0 
AMT All Median 15.0 21.6 14.1 
IQR 2.3-34.8 12.5-125.8 1.9-32.3 
Tablet Median 7.7 12.8 7.7 
IQR 0.0-18.8 0.0-25.1 0.0-18.3 
Oral liquid Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.9 0.0-0.0 
Injectable Median 0.0 0.0 0.2 
IQR 0.0-9.5 0.0-20.0 0.0-8.2 
nAT All Median 304.9 236.2 350.7 
IQR 52.1-1523.7 25.8-3822.6 109.1-1828.3 
Tablet Median 203.8 122.0 244.4 
IQR 10.3-1053.9 0.0-3642.9 69.4-1348.4 
Oral liquid Median 28.8 32.5 32.3 
IQR 3.6-78.8 0.0-77.2 10.2-81.1 
Injectable Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
 ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
N=126 N=46 N=104 
RDT
4
 (units)  Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic 
test for malaria; 2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, 
suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or 
granules, and so few of these product types were observed during the audit, these dosage forms have been excluded from the tables 
here, but are provided in the appendix as supplemental tables. 3 For antimalarials: there were a total of 127wholesalers with 
antimalarial sales volumes (reported or imputed or set as null if did not stock). Note on imputation process for antimalarial sales 
volumes: during the study, 142 wholesalers were identified, of which 127 were interviewed and 4 refused (Table 1).   Out of the 127 
interviewed, 1 did not stock antimalarials at the time of the survey, so their sales volumes were set as zero for all antimalarial 
categories.  The volumes for 14 wholesalers were set as missing for all antimalarial categories: 6 businesses had closed down, 2 
wholesalers could not be located, 4 refused and had antimalarials in stock, and 2 reported stocking antimalarials but no audit sheet 
information was recorded.  Overall, there were a total of 1326 antimalarials audited, of which 45 (3.4%) had missing sales volumes 
that were imputed using the mi impute pmm command.  4 For RDTs, 105 wholesalers reported that they did not stock RDTs, 3 did not 
know if they stocked RDTs at any point in the three months prior to interview, and 24 reported stocking RDT from whom inventory 
data were collected from 23 wholesalers on 25 observed products.  Of these, information on sales volume was not provided for 3 
products from 3 different wholesalers; however imputation was not performed as there were too few observations to reliably 
perform linear regression.  Sales volumes were set as missing for the 1 wholesaler who reported stocking RDTs but from whom 
inventory data were not collected.  Therefore for RDTs, median sales volumes at the level supplying retail outlets are estimated 
based on the sample of 22 products from 20 wholesalers for which volumes were not missing. 
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Table 4.8.2: Median number of AETDs & RDTs sold during the week preceding the survey (among 
wholesalers stocking corresponding antimalarial drug category/RDT at the time of the survey) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES
3
 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
All ACT All Median 30.0 74.0 23.0 
IQR 10.0-99.9 21.2-344.8 8.9-60.4 
(n) (113) (46) (91) 
Tablet Median 31.2 84.4 25.5 
IQR 11.7-97.8 25.2-344.4 10.4-72.4 
(n) (108) (43) (88) 
Oral liquid Median 1.7 3.8 1.5 
IQR 0.4-4.3 1.1-7.5 0.4-3.8 
(n) (36) (19) (29) 
WHO-
prequalified 
ACT 
All products were 
tablets 
Median 10.0 20.0 10.0 
IQR 5.0-40.0 10.0-50.0 5.0-30.0 
(n) (67) (25) (57) 
Non-WHO-
prequalified 
ACT 
All Median 18.3 50.7 15.2 
IQR 5.4-85.8 9.3-243.4 5.0-48.8 
(n) (96) (40) (78) 
Tablet Median 20.0 64.4 16.3 
IQR 8.6-82.1 18.3-236.1 6.2-54.4 
(n) (89) (36) (73) 
Oral liquid Median 1.7 3.8 1.5 
IQR 0.4-4.3 1.1-7.5 0.4-3.8 
(n) (36) (19) (29) 
AMT All Median 20.5 28.4 18.9 
IQR 10.1-62.5 15.6-150.0 8.6-34.8 
(n) (103) (41) (85) 
Tablet Median 13.8 18.5 12.5 
IQR 6.3-26.9 10.8-43.8 5.6-22.1 
(n) (92) (34) (78) 
Oral liquid Median 1.6 1.6 1.6 
IQR 0.6-6.3 1.3-6.3 0.6-6.3 
(n) (29) (15) (23) 
Injectable Median 8.3 20.0 7.1 
IQR 2.4-30.0 5.9-147.9 2.3-23.8 
(n) (65) (24) (56) 
nAT All Median 372.7 750.5 441.0 
IQR 125.0-2092.8 81.2-4306.3 142.4-2092.8 
(n) (114) (39) (97) 
Tablet Median 404.8 688.1 420.0 
IQR 111.4-1546.8 119.0-6000.0 111.9-1738.1 
(n) (105) (35) (91) 
Oral liquid Median 33.9 47.6 33.7 
IQR 16.5-85.8 31.7-158.4 16.5-99.2 
(n) (106) (33) (94) 
Injectable Median 22.0 238.1 20.2 
IQR 4.8-119.0 19.0-1190.5 4.8-95.2 
(n) (58) (14) (55) 
RDT (units) Median 10 15 8.5 
IQR 0-25 2.5-50.5 0-50 
(n) (22) (16) (18) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for 
malaria.  2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, 
injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types 
were observed during the audit, these dosage forms have been excluded from the tables here, but are provided in the appendix as supplemental 
tables. 3 (n) is the number of wholesalers at a given level who stocked antimalarials for corresponding drug category or who stocked RDT. 
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4.9. Purchase price of antimalarials and RDTs 
Purchase price is the price paid by businesses (i.e. wholesalers or outlets) for their most recent purchase of an 
antimalarial product from their suppliers, and is reported in terms of the median price (in US dollars) per AETD.  
Because of the varied nature of wholesaler transactions (e.g. wholesalers may vary their price; antimalarials may pass 
through a number of wholesalers before reaching an outlet), wholesale purchase prices are indicative of the purchase 
prices paid by wholesalers in general, rather than at specific levels of the supply chain.  Retail purchase prices, however, 
reflect the antimalarial purchase prices paid by specific outlet types to their suppliers. 
Among all wholesalers, the median wholesale purchase price per AETD ranged from US$ 1.17 (IQR 0.22-3.95) 
for nATs, to US$ 4.39 (IQR 2.44-7.56) for ACTs, and US$ 6.34 (IQR 4.68-9.76) for AMTs. Considering only oral 
dosage forms, median wholesale purchase prices were comparable for ACTs and AMTs for tablets (US$ 4.14 
for ACTs vs. US$ 5.08 for AMT) and oral liquids (US$ 12.69 for ACTs vs. US$ 10.15 for AMTs). The median 
purchase price for RDTs at wholesale level was US$ 0.78 per test. 
 Across different wholesale levels of the supply chain, purchase prices tended to be similar; however, the 
median purchase price for WHO-prequalified ACTs was observed to be lower among wholesalers 
supplying retailers (US$ 3.12, IQR 2.34-7.32) than those supplying other wholesalers (US$ 4.76, IQR 
2.34-7.56).  This was because a higher proportion of ACT products stocked by wholesalers supplying 
other wholesalers was Coartem (62% vs. 42% among wholesalers supplying retailers), which is the 
originator brand of AL, with a higher median purchase price than other brands of WHO-prequalified AL. 
 Across different retail outlet types, the median retail purchase price per AETD for ACTs ranged from US$ 
2.27 (IQR 0.71-3.79) in drug stores to US$ 6.39 (IQR 4.15-7.57) in pharmacies; for AMTs from US$ 6.06  
(IQR 3.03-10.22) in private health facilities to US$ 6.43 (IQR 4.54-9.73) in pharmacies; and for nATs from 
US$ 0.09 (IQR 0.00-0.50) in other private outlets, such as grocery stores, to US$ 0.79 (IQR 0.30-2.98) in 
pharmacies.  Pharmacies tended to have paid higher purchase prices for ACTs than other outlet types.  
For example, the median purchase price of WHO-prequalified ACT paid by pharmacies was US$ 7.10, 
compared to US$ 3.08 in private health facilities and US$ 3.79 in drug stores.  Public health facilities did 
not typically pay for their antimalarial purchases; however in a few instances, some public health 
facilities reported having paid to purchase AMTs and nATs.  
 Examining the effect of subsidised ACTs on retail purchase price in drug stores, the median price per 
AETD for all ACTs fell from US$ 2.27 (IQR 0.71-3.79) to US$ 0.47 (IQR 0.24-2.84) when observations from 
sub-districts participating in the pilot programme are included (described in section 2 above), and from 
US$ 3.79 (IQR 2.37-4.73) to US$ 0.26 (IQR 0.19-1.80) for WHO-prequalified ACTs. 
 For AL, the first-line treatment for uncomplicated Pf malaria, the median purchase price per AETD at 
wholesale level was US$ 4.29 (IQR 1.81-7.81) among wholesalers supplying other wholesalers, and US$ 
3.17 (IQR 1.95-7.81) among wholesalers supplying retailers.  At retail level, the median purchase price 
was US$ 7.10 (IQR 3.08-8.52) at pharmacies, US$ 3.08 (IQR 2.13-5.27) at private health facilities, and 
US$ 2.27 (IQR 1.80-3.79) at drug stores. 
 For SP, the antimalarial with the highest number of AETDs distributed, the median purchase price per 
AETD was US$ 0.33 (IQR 0.14-0.71) at pharmacies, US$ 0.13 (IQR 0.08-0.28) at private health facilities, 
US$ 0.12 (IQR 0.06-0.24) at drug stores, and US$ 0.09 (IQR 0.00-0.11) at other private outlets, such as 
grocery stores; at the wholesale level, the median purchase price was US$ 0.15 (IQR 0.10-0.40). 
 Regarding the recommended treatments for severe Pf malaria, the median purchase price per AETD for 
injectable quinine at wholesale level was US$ 4.61 (IQR 3.79-8.20); and at retail level, US$ 4.97 (IQR 
3.89-8.45) at pharmacies, US$ 4.97 (IQR 2.98-7.95) at private health facilities, and US$ 4.97 (IQR 3.97-
6.96) at drug stores. For injectable artemether, the median purchase price per AETD at wholesale level 
was US$ 9.27 (IQR 7.03-11.22); and at retail level, US$ 10.22 (IQR 6.81-11.36) at pharmacies, US$ 9.46 
(IQR 4.09-14.19) at private health facilities, and US$ 11.36 (IQR 5.52-19.30) at drug stores. 
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 Median purchase prices per AETD for tablets were lower compared to oral liquids across all antimalarial 
types and for both wholesalers and retailers.  Injectables tended to have the highest purchase prices, 
except for AMTs where oral liquids were observed to have higher purchase prices than injectables at 
wholesale level.   
 In several cases, the median price retailers paid to purchase antimalarials were observed to be lower 
than the prices paid by wholesalers, particularly among drug stores and private health facilities; while 
the reasons for this are not immediately clear, this may be the effect of differences in the restocking 
practices at different levels of the supply chain combined with exchange rate volatility, or preferences 
of different retailer types to stock a product mix different to wholesalers (e.g. drug stores may prefer to 
stock more generic than branded products.) 
 Where RDTs were stocked, wholesalers at all levels of supply chain reported purchasing 1 RDT unit at 
US$ 0.78 (IQR 0.73-0.88) (data were not collected on retailer purchase prices for RDTs).
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Table 4.9.1 Purchase price per AETD/RDT (US$), wholesale level 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
N=127 N=48 N=104 
All ACT All Median 4.39 4.39 4.39 
IQR 2.44-7.56 2.20-7.56 2.44-7.56 
(n) (277) (115) (234) 
Tablet Median 4.14 4.20 4.20 
IQR 2.17-5.86 1.95-5.86 2.20-5.86 
(n) (232) (94) (196) 
Oral liquid Median 12.69 11.84 13.01 
IQR 7.81-13.29 7.81-13.01 8.13-14.18 
(n) (38) (20) (32) 
WHO-
prequalified 
ACT 
All products 
were tablets 
Median 3.15 4.76 3.12 
IQR 2.27-7.44 2.34-7.56 2.34-7.32 
(n) (84) (30) (73) 
Non WHO-
prequalified 
ACT 
All Median 4.53 4.39 4.67 
IQR 2.44-7.56 2.20-7.32 3.42-7.81 
(n) (193) (85) (161) 
Tablet Median 4.36 4.20 4.39 
IQR 1.95-5.61 1.76-4.94 2.20-5.76 
(n) (148) (64) (123) 
Oral liquid Median 12.69 11.84 13.01 
IQR 7.81-13.29 7.81-13.01 8.13-14.18 
(n) (38) (20) (32) 
AMT All Median 6.34 6.49 6.30 
IQR 4.68-9.76 4.68-9.56 4.68-9.76 
(n) (293) (110) (254) 
Tablet Median 5.08 4.84 5.08 
IQR 3.90-6.25 3.90-6.25 3.90-6.17 
(n) (162) (61) (140) 
Oral liquid Median 10.15 10.54 10.15 
IQR 9.37-14.05 9.68-14.05 9.37-14.31 
(n) (27) (14) (22) 
Injectable Median 9.27 8.39 9.37 
IQR 7.03-11.22 6.34-10.71 7.32-11.22 
(n) (103) (35) (91) 
nAT All Median 1.17 1.17 1.17 
IQR 0.22-3.95 0.22-3.90 0.22-4.10 
(n) (621) (182) (570) 
Tablet Median 0.22 0.22 0.22 
IQR 0.13-1.74 0.13-1.74 0.13-1.74 
(n) (299) (89) (272) 
Oral liquid Median 1.32 1.35 1.32 
IQR 0.61-5.30 0.65-5.38 0.61-5.33 
(n) (253) (72) (232) 
Injectable Median 4.61 4.00 4.61 
IQR 3.69-8.20 3.07-7.17 3.69-8.20 
(n) (66) (19) (63) 
RDT (per unit) Median 0.78 0.78 0.78 
IQR (0.73-0.88) (0.73-0.88) (0.73-0.88) 
(n) (19) (15) (15) 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: 
Rapid diagnostic test for malaria. 2 The values for ‘all’ formulations include all dosage forms (tablets, suppositories, 
oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or 
granules, and so few of these product types were observed during the audit, these dosage forms have been excluded 
from the tables here. 
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Table 4.9.2 Purchase price per AETD (US$), retail level  
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4
 
PUBLIC 
HEALTH 
FACILITIES 
N=87 N=176 N=352 N=9 N=198 
All ACT
5
 All Median 6.39 3.31 2.27 - 0.00 
IQR 4.15-7.57 2.13-4.52 0.71-3.79 - 0.00-0.00 
(n) (243) (69) (52) - (233) 
Tablet Median 5.32 3.31 2.27 - 0.00 
IQR 3.41-7.10 2.13-4.52 0.71-3.79 - 0.00-0.00 
(n) (205) (63) (49) - (233) 
Oral liquid Median 12.62 8.20 2.31 - - 
IQR 12.62-12.62 0.00-9.46 0.00-2.31 - - 
(n) (30) (5) (3) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 7.10 3.08 3.79 - 0.00 
IQR 4.73-7.33 0.00-7.45 2.37-4.73 - 0.00-0.00 
(n) (82) (13) (11) - (225) 
Non WHO-
prequalified 
ACT
5
 
All Median 5.32 3.46 2.13 - 0.00 
IQR 3.99-8.20 2.13-4.52 0.47-3.79 - 0.00-0.00 
(n) (161) (56) (41) - (8) 
Tablet Median 4.52 3.41 2.13 - 0.00 
IQR 3.09-5.68 2.13-4.36 0.47-3.79 - 0.00-0.00 
(n) (123) (50) (38) - (8) 
Oral liquid Median 12.62 8.20 2.31 - - 
IQR 12.62-12.62 0.00-9.46 0.00-2.31 - - 
(n) (30) (5) (3) - - 
AMT All Median 6.43 6.06 6.06 - 6.06 
IQR 4.54-9.73 3.03-10.22 4.16-7.57 - 6.06-11.36 
(n) (213) (89) (40) - (3) 
Tablet Median 5.68 5.30 4.92 - 6.06 
IQR 4.02-7.27 3.03-6.81 3.79-6.06 - 6.06-6.06 
(n) (119) (53) (31) - (1) 
Oral liquid Median 6.81 11.36 11.36 - - 
IQR 6.81-9.84 0.00-11.36 11.36-11.36 - - 
(n) (20) (6) (3) - - 
Injectable Median 10.22 9.46 11.36 - 11.36 
IQR 6.81-11.36 4.09-14.19 5.52-19.30 - 11.36-11.36 
(n) (71) (30) (6) - (2) 
nAT All Median 0.79 0.71 0.59 0.09 0.00 
IQR 0.30-2.98 0.14-2.44 0.14-1.99 0.00-0.50 0.00-0.07 
(n) (526) (735) (1369) (14) (347) 
Tablet Median 0.33 0.21 0.21 0.09 0.00 
IQR 0.17-0.89 0.09-0.80 0.08-0.89 0.00-0.20 0.00-0.06 
(n) (277) (412) (775) (12) (181) 
Oral liquid Median 1.70 2.13 1.70 3.91 4.40 
IQR 0.79-4.15 0.79-4.40 0.63-4.40 3.91-3.91 3.35-4.89 
(n) (191) (215) (513) (1) (10) 
Injectable Median 4.83 4.97 4.97 3.97 0.00 
IQR 3.48-8.45 2.84-7.95 3.53-6.96 3.97-3.97 0.00-0.00 
(n) (58) (108) (81) (1) (156) 
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1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 
 
As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs. Data in table 4.9.2 are 
presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.9.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
 
 
 
Table 4.9.3 Purchase price per AETD (US$), retail level INCLUDING subsidised ACT products 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4
 
PUBLIC 
HEALTH 
FACILITIES 
N=87 N=176 N=352 N=9 N=198 
All ACT
5
 All Median 6.12 3.31 0.47 - 0.00 
IQR 3.73-7.57 2.13-4.52 0.24-2.84 - 0.00-0.00 
(n) (248) (69) (65) - (233) 
Tablet Median 5.32 3.31 0.47 - 0.00 
IQR 3.08-7.10 2.13-4.52 0.24-3.19 - 0.00-0.00 
(n) (210) (63) (62) - (233) 
Oral liquid Median 12.62 8.20 2.31 - - 
IQR 12.62-12.62 0.00-9.46 0.00-2.31 - - 
(n) (30) (5) (3) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 7.10 3.08 0.26 - 0.00 
IQR 3.08-7.24 0.00-7.45 0.19-1.80 - 0.00-0.00 
(n) (87) (13) (24) - (225) 
Non WHO-
prequalified 
ACT
5 
All Median 5.32 3.46 2.13 - 0.00 
IQR 3.99-8.20 2.13-4.52 0.47-3.79 - 0.00-0.00 
(n) (161) (56) (41) - (8) 
Tablet Median 4.52 3.41 2.13 - 0.00 
IQR 3.09-5.68 2.13-4.36 0.47-3.79 - 0.00-0.00 
(n) (123) (50) (38) - (8) 
Oral liquid Median 12.62 8.20 2.31 - - 
IQR 12.62-12.62 0.00-9.46 0.00-2.31 - - 
(n) (30) (5) (3) - - 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs. Data in table 4.9.2 are 
presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.9.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
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4.10. Price mark-ups on antimalarials and RDTs 
4.10.1.  Percent Mark-Ups on Antimalarials and RDTs 
In general, the percentage mark-up is calculated as the difference between the selling price and the purchase price, 
divided by the purchase price.  It captures both the costs of doing business and profit to the seller.  Because 
wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using data on minimum and 
maximum selling price charged for one unit by wholesalers.  The wholesale percent mid mark-up was calculated as the 
difference between the average wholesale selling price (i.e. the mid-point between the maximum and minimum 
wholesale selling price) and wholesale purchase price, divided by wholesale purchase price.  The retail percent mark-up 
was calculated using the retail selling price and purchase price collected during the ACTwatch Outlet Survey.
8
 
At wholesale level, percent mark-ups were relatively low and consistent both across antimalarial categories 
and dosage forms, ranging from 14% on ACTs, to 15% on AMTs and 18% on nATs.  Percent mark-ups among 
retailers tended to be higher than at wholesale level, and mark-ups above 100% were commonly observed in 
drug stores and for nATs across all retailer categories. 
 Wholesale-level median mid percent mark-ups did not vary much across antimalarial categories or 
dosage forms: they ranged from 14.3% for ACTs to 17.6% for nATs; and across dosage forms from 15.4% 
for tablets to 20.0% for oral liquids and injectables.   
 Wholesalers reported varying their mark-up on 42.1% of all observed products depending on the volume 
being purchased (based on the 1194 observations where mark-up data were obtained), with similar 
percentages varying mark-ups across different levels of the supply chain. The difference between the 
highest and lowest median mark-ups was generally less than 5%, except for nATs, where the difference 
between highest and lowest mark-ups was 13% for oral liquids. 
 Among wholesalers, median mid percent mark-ups were observed to be slightly higher among 
wholesalers supplying retailers than those supplying other wholesalers (except for AMTs where percent 
mark-ups were similar across wholesale supply chain levels).  
 Retail median percent mark-ups were observed to be generally higher than those for wholesalers, 
ranging from 33.3%-87.5% across outlet types and antimalarial categories.  
 It was rare for public health facilities to report taking payments for antimalarials, and the percent mark-
ups added were relatively low, ranging from 15.0% to 32.5%. 
 Across different retail outlet types, the median percent mark-up on ACT ranged between 33.3% (IQR 
20.0-100.0) in drug stores and 43.6% (IQR 15.4-76.5) in private health facilities; on AMT between 33.3% 
(IQR 25.0-126.4) at drug stores and 60.0% (IQR 25.0-114.3) at private health facilities; on nAT between 
66.7% (IQR 33.3-150.0) at drug stores and 87.5% (IQR 38.9-250.9) at private health facilities.  
Pharmacies, private health facilities and drug stores were observed to apply higher percent mark-ups for 
non-WHO-prequalified ACT tablets than prequalified ACT tablets. 
 In drug stores, median percent mark-ups for ACTs were generally higher when observations from sub-
districts participating in the subsidised ACT pilot programme are included (described in section 2 above); 
for example, the median mark-up on WHO-prequalified ACT was 42.9% (IQR 33.3-100.0) when 
subsidised ACTs are included, and 31.6% (IQR 12.5-50.0) when excluded. 
 For AL, the first-line treatment for uncomplicated Pf malaria, the median retail percent mark-up was 
33.3% (IQR 23.1-50.0) at pharmacies, 42.9% (IQR 25.0-75.0) at private health facilities, and 33.3% (IQR 
20.0-100.0) at drug stores; at wholesale levels, the median mid percent mark-up was 11.3% (IQR 5.7-
25.0) among those supplying wholesalers, and 14.3% (IQR 7.2-25.0) among those supplying retailers.  
 For SP, the antimalarial with the highest number of AETDs distributed, the median retail percent mark-
up was 100.0% (IQR 66.7-350.0) at pharmacies, 200.0% (IQR 68.0-525.0) at private health facilities, and 
177.8% (IQR 66.7-455.6) at drug stores; at wholesale levels, the median mid percent mark-up was 12.9% 
(IQR 6.7-25.0) among wholesalers supplying wholesalers, and 23.1% (IQR 9.1-45.8) among wholesalers 
supplying retailers. 
                                                          
8
 Negative % mark-ups were recorded in several cases, for which there are several possible explanations:  (1) data collection errors 
(e.g. antimalarials bought in relatively large pack sizes and sold by the tablet were sometimes subject to errors); (2) some businesses 
may have sold products at lower prices than at which they were bought to deal with slow moving products or because the purchase 
price has increased and the business was still selling the ‘old’ product at the ‘old’ price.  
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 Regarding the recommended treatments for severe Pf malaria, the median percent mark-up for injectable quinine at wholesale level was 25.0% (IQR 
20.0-30.0); and at retail level, 25.0% (IQR 17.6-50.0) at pharmacies, 150.0% (IQR 60-828.5) at private health facilities, and 87.5% (IQR 42.9-150.0) at 
drug stores. For injectable artemether, the median percent mark-up per AETD at wholesale level was 11.8% (IQR 6.3-22.7); and at retail level, 40.0% 
(IQR 31.3-66.7) at pharmacies, 70.0% (IQR 33.3-122.2) at private health facilities, and 20.0% (IQR -17.6-50.0) at drug stores. 
 The wholesale median mid percent mark-up on RDTs was 26.7% (IQR 20.0-33.3) among wholesalers supplying other wholesalers, and 17.6% (IQR 17.6-
17.6) among those supplying retailers. 
 
Table 4.10.1.1: Percent price mark-ups on antimalarials and RDTs, wholesale level (%) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS 
N=127 
SUPPLY WHOLESALERS 
N=48 
SUPPLY RETAILERS 
N=104 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
All ACT All Median 14.3 11.1 16.7 10.7 8.6 12.5 13.6 11.1 15.4 
IQR 7.1-25.0 5.9-20.0 8.1-28.6 5.4-24.0 4.2-18.2 6.3-28.6 6.7-25.0 5.4-18.8 7.5-26.3 
(n)  (277)   (115)   (234)  
Tablet Median 14.3 11.1 16.7 10.2 8.2 12.5 14.1 11.1 16.3 
IQR 7.1-25.0 5.9-20.0 8.3-28.6 5.4-22.7 3.8-16.7 6.3-27.3 7.1-25.0 5.9-19.4 7.9-26.7 
(n)  (232)   (94)   (196)  
Oral liquid Median 14.8 11.1 15.6 14.6 11.1 14.6 9.7 7.9 9.7 
IQR 6.7-22.2 5.0-18.2 6.7-30.0 5.3-27.3 5.1-17.9 5.3-39.4 5.3-18.2 5.0-17.2 5.3-19.1 
(n)  (38)   (20)   (32)  
WHO-
prequalified 
ACT 
All products 
were tablets 
Median 14.8 11.1 16.7 9.5 6.9 11.3 14.3 11.1 16.7 
IQR 7.5-25.8 6.1-18.5 8.0-29.3 4.5-22.2 3.2-16.7 4.5-26.7 7.1-25.0 5.9-18.2 7.5-27.9 
(n)  (84)   (30)   (73)  
Non WHO-
prequalified 
ACT 
All Median 14.3 11.1 16.7 11.4 10.0 12.5 13.3 10.2 15.4 
IQR 6.7-25.0 5.7-22.2 8.1-28.6 5.7-24.0 5.0-18.2 6.3-28.6 6.7-25.0 5.4-20.0 7.6-25.0 
(n)  (193)   (85)   (161)  
Tablet Median 13.6 11.1 16.3 11.1 8.6 12.5 13.3 11.1 16.0 
IQR 7.1-25.0 5.9-22.4 8.3-28.6 5.7-22.8 4.2-17.0 6.3-27.6 7.1-25.0 5.9-21.2 8.1-26.3 
(n)  (148)   (64)   (123)  
Oral liquid Median 14.8 11.1 15.6 14.6 11.1 14.6 9.7 7.9 9.7 
IQR 6.7-22.2 5.0-18.2 6.7-30.0 5.3-27.3 5.1-17.9 5.3-39.4 5.3-18.2 5.0-17.2 5.3-19.1 
(n)  (38)   (20)   (32)  
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ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS 
N=127 
SUPPLY WHOLESALERS 
N=48 
SUPPLY RETAILERS 
N=104 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
AMT All Median 15.0 11.1 16.7 14.7 11.1 16.7 14.4 11.1 15.4 
IQR 7.5-28.6 6.3-22.4 8.3-33.3 6.7-28.6 5.3-20.0 7.7-33.3 7.5-25.0 6.3-22.7 8.3-30.4 
(n)  (293)   (110)   (254)  
Tablet Median 15.4 12.5 17.2 14.7 10.0 16.7 15.2 12.5 16.7 
IQR 7.7-29.8 6.7-23.1 7.9-33.3 5.8-29.3 4.9-16.7 7.1-33.3 7.7-29.2 6.9-25.0 8.1-33.3 
(n)  (162)   (61)   (140)  
Oral liquid Median 15.4 11.1 16.7 15.2 11.1 16.0 14.7 11.1 16.0 
IQR 8.3-29.2 6.7-23.1 10.3-33.3 8.9-22.2 7.1-16.7 11.1-33.3 7.3-23.1 6.7-23.1 9.1-23.1 
(n)  (27)   (14)   (22)  
Injectable Median 11.8 9.5 12.5 13.8 12.2 16.7 11.1 9.4 12.5 
IQR 6.3-22.7 5.9-20.0 7.1-25.0 5.7-28.6 5.3-25.7 7.1-28.6 6.4-20.0 5.9-20.0 7.1-23.1 
(n)  (103)   (35)   (91)  
nAT All Median 17.6 12.5 20.0 10.6 7.1 12.5 17.6 13.0 20.0 
IQR 8.6-35.1 6.3-25.0 10.0-44.4 5.6-25.0 4.3-18.8 5.9-31.6 8.7-35.0 6.3-25.0 10.2-42.9 
(n)  (623)   (182)   (572)  
Tablet Median 15.4 12.5 17.2 9.4 7.1 11.8 15.4 12.5 17.6 
IQR 6.7-35.0 6.2-25.0 7.1-38.2 4.8-18.8 4.0-16.7 5.9-25.0 7.0-35.0 6.3-25.0 7.1-40.0 
(n)  (300)   (89)   (273)  
Oral liquid Median 20.0 12.5 25.0 11.1 6.5 14.3 20.0 12.5 25.0 
IQR 9.4-38.9 6.3-25.0 11.1-50.0 5.6-29.3 4.8-20.0 5.9-39.2 9.4-38.9 6.3-25.0 11.1-50.0 
(n)  (254)   (72)   (233)  
Injectable Median 20.0 17.3 25.0 16.9 15.4 16.9 20.0 17.6 25.0 
IQR 11.1-29.2 8.1-25.0 12.5-33.3 6.8-30.0 5.4-30.0 8.1-33.3 11.3-29.2 8.6-25.0 12.5-33.3 
(n)  (66)   (19)   (63)  
RDT (per unit) Median 20.0 17.6 20.0 26.7 20.0 33.3 17.6 17.6 17.6 
IQR 10.0-44.4 6.7-40.0 11.1-44.4 10.0-44.4 6.7-44.4 11.1-50.0 10.0-38.9 6.7-38.9 11.1-38.9 
(n)  (19)   (15)   (15)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for ‘all’ formulations include all 
dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types 
were observed during the audit, these dosage forms have been excluded from the tables here. 
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 Table 4.10.1.2: Percent price mark-ups on antimalarials, retail level (%) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4 
PUBLIC 
HEALTH 
FACILITIES 
N=89 N=173 N=349 N=9 N=197 
All ACT
5 
All Median 42.9 43.6 33.3 - 0.0 
IQR 23.1-52.5 15.4-76.5 20.0-100.0 - 0.0-0.0 
(n) (240) (61) (48) - (230) 
Tablet Median 42.9 42.9 40.0 - 0.0 
IQR 23.1-60.0 11.1-76.5 25.0-100.0 - 0.0-0.0 
(n) (202) (56) (47) - (230) 
Oral liquid Median 50.0 53.8 9.1 - - 
IQR 25.0-50.0 33.3-66.7 9.1-9.1 - - 
(n) (30) (4) (1) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 33.3 25.0 31.6 - 0.0 
IQR 13.9-33.3 -55.6-38.5 12.5-50.0 - 0.0-0.0 
(n) (81) (10) (10) - (222) 
Non WHO-
prequalified 
ACT
5
 
All Median 50.0 53.8 33.3 - 0.0 
IQR 26.3-76.5 20.0-84.6 25.0-140.0 - 0.0-0.0 
(n) (159) (51) (38) - (8) 
Tablet Median 50.0 50.0 42.9 - 0.0 
IQR 28.6-76.5 15.4-84.6 25.0-140.0 - 0.0-0.0 
(n) (121) (46) (37) - (8) 
Oral liquid Median 25.0 33.3 9.1 - - 
IQR 25.0-50.0 33.3-66.7 9.1-9.1 - - 
(n) (30) (4) (1) - - 
AMT All Median 41.2 60.0 33.3 - 15.0 
IQR 25.0-56.3 25.0-114.3 25.0-126.4 - 15.0-32.5 
(n) (210) (84) (38) - (3) 
Tablet Median 41.2 60.0 42.9 - 15.0 
IQR 20.0-50.0 25.0-114.3 25.0-138.1 - 15.0-15.0 
(n) (119) (51) (29) - (1) 
Oral liquid Median 55.6 33.3 33.3 - - 
IQR 50.0-55.6 33.3-36.4 33.3-33.3 - - 
(n) (20) (5) (3) - - 
Injectable Median 40.0 70.0 20.0 - 32.5 
IQR 31.3-66.7 33.3-122.2 -17.6-50.0 - 32.5-32.5 
(n) (68) (28) (6) - (2) 
nAT All Median 66.7 87.5 66.7 259.0 0.0 
IQR 42.9-100.0 38.9-250.9 33.3-150.0 25.0-16566.7 0.0-15.0 
(n) (515) (716) (1354) (15) (338) 
Tablet Median 66.7 100.0 100.0 1400.0 0.0 
IQR 50.0-233.3 50.0-455.6 50.0-300.0 25.0-16566.7 0.0-20.5 
(n) (267) (404) (768) (13) (177) 
Oral liquid Median 66.7 50.0 42.9 12.5 25.0 
IQR 42.9-92.3 25.0-87.5 25.0-66.7 12.5-12.5 15.0-38.9 
(n) (191) (208) (507) (1) (10) 
Injectable Median 25.0 150.0 87.5 25.0 0.0 
IQR 17.6-50.0 50.0-828.6 42.9-150.0 25.0-25.0 0.0-0.0 
(n) (57) (104) (79) (1) (151) 
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1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs. Data in table 4.10.1.2 
are presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.10.1.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
 
Table 4.10.1.3: Percent price mark-ups on antimalarials, retail level, INCLUDING subsidised ACT products (%) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4 
PUBLIC 
HEALTH 
FACILITIES 
N=89 N=173 N=349 N=9 N=197 
All ACT
5 
All Median 42.9 43.6 42.9 - 0.0 
IQR 23.1-52.5 15.4-76.5 31.6-100.0 - 0.0-0.0 
(n) (245) (61) (61) - (230) 
Tablet Median 42.9 42.9 42.9 - 0.0 
IQR 23.1-60.0 11.1-76.5 33.3-100.0 - 0.0-0.0 
(n) (207) (56) (60) - (230) 
Oral liquid Median 50.0 53.8 9.1 - - 
IQR 25.0-50.0 33.3-66.7 9.1-9.1 - - 
(n) (30) (4) (1) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 33.3 25.0 42.9 - 0.0 
IQR 13.9-36.4 -55.6-38.5 33.3-100.0 - 0.0-0.0 
(n) (86) (10) (23) - (222) 
Non WHO-
prequalified 
ACT
5
 
All Median 50.0 53.8 33.3 - 0.0 
IQR 26.3-76.5 20.0-84.6 25.0-140.0 - 0.0-0.0 
(n) (159) (51) (38) - (8) 
Tablet Median 50.0 50.0 42.9 - 0.0 
IQR 28.6-76.5 15.4-84.6 25.0-140.0 - 0.0-0.0 
(n) (121) (46) (37) - (8) 
Oral liquid Median 50.0 53.8 9.1 - - 
IQR 25.0-50.0 33.3-66.7 9.1-9.1 - - 
(n) (30) (4) (1) - - 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs.  Data in table 4.10.1.2 
are presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.10.1.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
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4.10.2. Absolute mark-ups on antimalarials and RDTs (US$) 
In general, the absolute mark-up is calculated as the difference between the selling price and the purchase price per 
AETD and is reported in US dollars.  It captures both the costs of doing business and profit to the seller. Because 
wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using data on minimum and 
maximum selling price charged per AETD by wholesalers.  The wholesale absolute mid mark-up was calculated as the 
difference between the average wholesale selling price (i.e. the mid-point between the maximum and minimum 
wholesale selling price) and wholesale purchase price.  The retail absolute mark-up was calculated using the retail 
selling price and purchase price collected during the ACTwatch Outlet Survey.  Data were collected in local currencies 
and converted to their US$ equivalent using the average interbank rate for the duration of the fieldwork period. 
 
 The wholesale median mid absolute mark-up was US$ 0.59 (IQR 0.24-1.20) on ACT, US$ 0.49 (IQR 0.24-
0.85) on WHO-prequalified ACT, US$ 0.61 (IQR 0.27-1.37) on non-WHO-prequalified ACT, US$ 0.94 (IQR 
0.39-1.80) on AMT and US$ 0.20 (IQR 0.05-0.59) on nAT. 
 Wholesalers supplying retailers tended to apply higher absolute mark-ups than those supplying other 
wholesalers.  This is because wholesalers supplying retailers tended to apply higher percent mark-ups (as 
noted above in section 4.10.1), as purchase prices tended to be similar across different chain levels of. 
 As noted in section 4.10.1, it was common for wholesalers to vary percent mark-ups applied depending 
on volumes purchased, and percent mark-ups applied by wholesalers supplying retailers tended to be 
higher than by those supplying other wholesalers.  Absolute mark-ups mirrored these patterns; however 
as expected, the magnitude of the observed differences between median high and low absolute mark-
ups was a function of purchase price (i.e. higher purchase price led to greater differences between 
median high and low absolute mark-ups). 
 Across different retail outlet types, the median absolute mark-up on ACTs ranged between US$ 0.95 (IQR 
0.47-2.65) at drug stores and US$ 2.37 (IQR 1.18-3.79) at pharmacies; on AMTs between US$ 2.84 (IQR 
1.51-5.07) at drug stores and US$ 5.00 (IQR 2.27-8.52) at private health facilities; and on nATs between 
US$ 0.44 (IQR 0.21-1.22) at drug stores and US0.74 (IQR 0.34-1.42) at pharmacies. 
 Pharmacies and private health facilities tended to have higher absolute mark-ups for antimalarials 
compared to drug stores, as drug stores stocked relatively cheaper products, fewer injectable products, 
more generic – rather than originator – products (e.g. among ACTs, Lonart vs. Coartem), and in the case 
of nATs, more locally manufactured products. 
 In drug stores, absolute price mark-ups for ACTs were generally lower when observations from sub-
districts participating in the subsidised ACT pilot programme are included (described in section 2 above); 
for example, the median absolute price mark-up on WHO-prequalified ACT was US$ 0.19 (IQR 0.09-0.25) 
when subsidised ACTs are included, and US$ 0.95 (IQR 0.47-1.42) when excluded. 
 For AL, the first-line treatment for uncomplicated Pf malaria, the median absolute retail mark-up was 
US$ 2.37 (IQR 1.04-3.79) at pharmacies, US$ 1.89 (IQR 0.95-3.31) at private health facilities, and US$ 
0.95 (IQR 0.47-2.78) at drug stores; at the wholesale level, the overall median absolute mark-up was US$ 
0.52 (IQR 0.24-1.22); however for tablets, wholesalers supplying retailers applied a higher median mid 
absolute mark-up (US$ 0.48, IQR 0.24-0.88) than those supplying other wholesalers (US$ 0.24, IQR 0.18-
0.61). 
 For SP, the antimalarial with the highest number of AETDs distributed, the median absolute retail mark-
up was US$ 0.47 (IQR 0.39-0.71) at pharmacies, US$ 0.35 (IQR 0.21-0.60) at private health facilities, and 
US$ 0.24 (IQR 0.14-0.38) at drug stores; at the wholesale level, median mid absolute mark-up was US$ 
0.04 (IQR 0.01-0.13). 
 Regarding the recommended treatments for severe Pf malaria, the median absolute mark-up per AETD 
for injectable quinine at wholesale level was US$ 0.73 (IQR 0.73-0.73); and at retail level, US$ 1.49 (IQR 
1.49-2.48) at pharmacies, US$ 6.16 (IQR 2.98-14.11) at private health facilities, and US$ 4.97 (IQR 2.98-
6.96) at drug stores. For injectable artemether, the median absolute mark-up per AETD at wholesale 
level was US$ 1.00 (IQR 0.50-1.95); and at retail level, US$ 4.54 (IQR 2.84-5.68) at pharmacies, US$ 8.52 
(IQR 3.89-12.49) at private health facilities, and US$ 3.79 (IQR -0.97-4.54) at drug stores. 
 The median wholesale mid mark-up on RDTs was US$ 0.19 (IQR 0.07-0.24) among wholesalers supplying 
other wholesalers, and US$ 0.15 (IQR 0.07-0.24) among wholesalers supplying retailers.  
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Table 4.10.2.1: Absolute price mark ups on antimalarials and RDTs, wholesale level (US$) 
 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS 
N=127 
SUPPLY WHOLESALERS 
N=48 
SUPPLY RETAILERS 
N=104 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
All ACT All Median 0.59 0.49 0.65 0.44 0.32 0.49 0.55 0.49 0.65 
IQR 0.24-1.20 0.24-0.98 0.27-1.37 0.22-1.10 0.15-0.78 0.24-1.22 0.24-1.17 0.24-0.98 0.27-1.30 
(n)  (277)   (115)   (234)  
Tablet Median 0.49 0.34 0.55 0.32 0.24 0.34 0.49 0.31 0.55 
IQR 0.24-0.98 0.24-0.77 0.24-1.17 0.20-0.78 0.15-0.59 0.24-0.98 0.24-1.00 0.24-0.75 0.24-1.17 
(n)  (232)   (94)   (196)  
Oral liquid Median 1.24 1.07 1.30 1.30 0.98 1.30 0.93 0.82 1.10 
IQR 0.65-2.60 0.65-2.60 0.65-3.25 0.65-2.93 0.65-2.60 0.65-3.60 0.65-2.60 0.65-2.28 0.65-2.60 
(n)  (38)   (20)   (32)  
WHO-
prequalified 
ACT 
All products 
were tablets 
Median 0.49 0.24 0.49 0.31 0.24 0.41 0.49 0.24 0.49 
IQR 0.24-0.85 0.24-0.59 0.24-0.98 0.20-0.73 0.12-0.49 0.24-0.78 0.24-0.85 0.24-0.49 0.24-0.98 
(n)  (84)   (30)   (73)  
Non WHO-
prequalified 
ACT 
All Median 0.61 0.49 0.73 0.44 0.39 0.49 0.65 0.49 0.73 
IQR 0.27-1.37 0.24-1.17 0.27-1.46 0.24-1.20 0.16-0.93 0.24-1.32 0.27-1.22 0.24-1.17 0.27-1.46 
(n)  (193)   (85)   (161)  
Tablet Median 0.49 0.34 0.55 0.32 0.27 0.34 0.49 0.34 0.59 
IQR 0.24-1.10 0.24-0.91 0.26-1.20 0.20-0.84 0.15-0.66 0.24-1.03 0.24-1.10 0.24-0.93 0.24-1.22 
(n)  (148)   (64)   (123)  
Oral liquid Median 1.24 1.07 1.30 1.30 0.98 1.30 0.93 0.82 1.10 
IQR 0.65-2.60 0.65-2.60 0.65-3.25 0.65-2.93 0.65-2.60 0.65-3.60 0.65-2.60 0.65-2.28 0.65-2.60 
(n)  (38)   (20)   (32)  
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ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS 
N=127 
SUPPLY WHOLESALERS 
N=48 
SUPPLY RETAILERS 
N=104 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
AMT All Median 0.94 0.70 1.17 0.89 0.67 1.17 0.84 0.68 0.99 
IQR 0.39-1.80 0.39-1.46 0.39-2.01 0.37-1.76 0.31-1.41 0.39-2.01 0.39-1.67 0.39-1.46 0.39-1.95 
(n)  (293)   (110)   (254)  
Tablet Median 0.76 0.55 0.78 0.59 0.39 0.73 0.72 0.52 0.78 
IQR 0.39-1.56 0.39-1.17 0.39-1.95 0.31-1.34 0.24-0.98 0.39-1.80 0.39-1.56 0.39-1.17 0.39-1.87 
(n)  (162)   (61)   (140)  
Oral liquid Median 1.48 1.09 1.56 1.56 1.20 1.56 1.33 1.02 1.56 
IQR 0.86-3.12 0.78-2.34 0.94-3.90 1.17-2.73 0.78-1.56 1.56-3.12 0.78-3.12 0.47-2.34 0.78-3.12 
(n)  (27)   (14)   (22)  
Injectable Median 1.00 0.82 1.17 1.17 1.17 1.17 1.00 0.80 1.17 
IQR 0.50-1.95 0.39-1.76 0.67-2.01 0.39-2.01 0.39-2.01 0.40-2.68 0.50-1.95 0.34-1.76 0.67-1.95 
(n)  (103)   (35)   (91)  
nAT All Median 0.20 0.15 0.24 0.13 0.08 0.15 0.20 0.15 0.23 
IQR 0.05-0.59 0.04-0.41 0.06-0.70 0.03-0.37 0.02-0.31 0.04-0.44 0.05-0.59 0.04-0.44 0.06-0.72 
(n)  (620)   (182)   (569)  
Tablet Median 0.06 0.05 0.07 0.04 0.03 0.05 0.07 0.05 0.07 
IQR 0.02-0.20 0.02-0.16 0.02-0.24 0.01-0.15 0.01-0.10 0.01-0.20 0.02-0.20 0.02-0.16 0.02-0.22 
(n)  (298)   (89)   (271)  
Oral liquid Median 0.36 0.29 0.44 0.23 0.15 0.31 0.34 0.26 0.44 
IQR 0.15-0.65 0.12-0.54 0.16-0.88 0.11-0.55 0.08-0.31 0.15-0.65 0.15-0.63 0.12-0.56 0.16-0.88 
(n)  (253)   (72)   (232)  
Injectable Median 1.02 1.02 1.18 0.82 0.67 1.02 1.02 1.02 1.23 
IQR 0.51-2.05 0.51-2.05 0.51-2.05 0.26-1.54 0.20-1.54 0.31-2.05 0.51-2.05 0.51-2.05 0.67-2.05 
(n)  (66)   (19)   (63)  
RDT (per unit) Median 0.15 0.15 0.15 0.19 0.15 0.23 0.15 0.15 0.15 
IQR 0.07-0.24 0.05-0.24 0.10-0.29 0.07-0.24 0.05-0.24 0.10-0.29 0.07-0.24 0.05-0.24 0.10-0.24 
(n)  (19)   (15)   (15)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for ‘all’ formulations include all 
dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types 
were observed during the audit, these dosage forms have been excluded from the tables here. 
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 Table 4.10.2.2: Absolute price mark ups on antimalarials, retail level (US$) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4 
PUBLIC 
HEALTH 
FACILITIES 
N=87 N=176 N=351 N=9 N=197 
All ACT
5 
All Median 2.37 2.30 0.95 - 0.00 
IQR 1.18-3.79 0.95-3.73 0.47-2.65 - 0.00-0.00 
(n) (240) (68) (52) - (232) 
Tablet Median 2.13 1.89 0.95 - 0.00 
IQR 1.06-3.46 0.83-3.41 0.47-2.65 - 0.00-0.00 
(n) (202) (62) (49) - (232) 
Oral liquid Median 6.31 4.42 0.21 - - 
IQR 3.79-6.31 3.15-10.09 0.21-10.09 - - 
(n) (30) (5) (3) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 1.42 1.18 0.95 - 0.00 
IQR 0.95-2.37 0.47-1.89 0.47-1.42 - 0.00-0.00 
(n) (81) (13) (11) - (224) 
Non WHO-
prequalified 
ACT
5
 
All Median 3.19 2.60 0.95 - 0.00 
IQR 1.86-3.79 1.06-4.26 0.24-2.78 - 0.00-0.00 
(n) (159) (55) (41) - (8) 
Tablet Median 2.66 2.30 0.95 - 0.00 
IQR 1.42-3.78 0.95-3.46 0.47-2.78 - 0.00-0.00 
(n) (121) (49) (38) - (8) 
Oral liquid Median 6.31 4.42 0.21 - - 
IQR 3.79-6.31 3.15-10.09 0.21-10.09 - - 
(n) (30) (5) (3) - - 
AMT All Median 3.03 5.00 2.84 - 0.91 
IQR 1.67-4.54 2.27-8.52 1.51-5.07 - 0.91-3.69 
(n) (211) (88) (40) - (3) 
Tablet Median 1.95 3.41 1.95 - 0.91 
IQR 1.66-3.03 1.51-5.92 1.51-5.30 - 0.91-0.91 
(n) (119) (53) (31) - (1) 
Oral liquid Median 3.79 5.30 3.79 - - 
IQR 3.79-4.54 3.79-12.11 3.79-3.79 - - 
(n) (20) (6) (3) - - 
Injectable Median 4.54 8.52 3.79 - 3.69 
IQR 2.84-5.68 3.89-12.49 -0.97-4.54 - 3.69-3.69 
(n) (69) (29) (6) - (2) 
nAT All Median 0.74 0.59 0.44 0.24 0.00 
IQR 0.34-1.42 0.23-1.66 0.21-1.22 0.14-0.42 0.00-0.19 
(n) (516) (728) (1365) (14) (345) 
Tablet Median 0.47 0.34 0.26 0.21 0.00 
IQR 0.18-0.95 0.18-0.62 0.13-0.51 0.14-0.42 0.00-0.17 
(n) (267) (410) (775) (12) (180) 
Oral liquid Median 1.14 1.18 0.74 0.49 0.71 
IQR 0.71-1.95 0.52-1.69 0.47-1.47 0.49-0.49 0.66-1.22 
(n) (191) (214) (511) (1) (10) 
Injectable Median 1.49 6.16 4.47 0.99 0.00 
IQR 1.14-2.48 2.98-14.11 1.99-5.96 0.99-0.99 0.00-0.00 
(n) (58) (104) (79) (1) (155) 
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1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs.  Data in table 4.10.2.2 
are presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.10.2.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
 
Table 4.10.2.3: Absolute price mark-ups on antimalarials, retail level INCLUDING subsidised ACT products (US$) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
OTHER 
PRIVATE 
OUTLETS
4 
PUBLIC 
HEALTH 
FACILITIES 
N=87 N=176 N=351 N=9 N=197 
All ACT
5
 All Median 2.37 2.30 0.25 - 0.00 
IQR 1.18-3.79 0.95-3.73 0.11-1.14 - 0.00-0.00 
(n) (245) (68) (65) - (232) 
Tablet Median 2.13 1.89 0.25 - 0.00 
IQR 1.04-3.46 0.83-3.41 0.11-1.14 - 0.00-0.00 
(n) (207) (62) (62) - (232) 
Oral liquid Median 6.31 4.42 0.21 - - 
IQR 3.79-6.31 3.15-10.09 0.21-10.09 - - 
(n) (30) (5) (3) - - 
WHO-
prequalified 
ACT
5
 
All products 
were tablets 
Median 1.38 1.18 0.19 - 0.00 
IQR 0.71-2.37 0.47-1.89 0.09-0.25 - 0.00-0.00 
(n) (86) (13) (24) - (224) 
Non WHO-
prequalified 
ACT
5
 
All Median 3.19 2.60 0.95 - 0.00 
IQR 1.86-3.79 1.06-4.26 0.24-2.78 - 0.00-0.00 
(n) (159) (55) (41) - (8) 
Tablet Median 2.66 2.30 0.95 - 0.00 
IQR 1.42-3.78 0.95-3.46 0.47-2.78 - 0.00-0.00 
(n) (121) (49) (38) - (8) 
Oral liquid Median 6.31 4.42 0.21 - - 
IQR 3.79-6.31 3.15-10.09 0.21-10.09 - - 
(n) (30) (5) (3) - - 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria. 2 The values reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and 
granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of these product types were 
observed during the audit, these dosage forms have been excluded from the tables here. 3 As these are weighted medians, medians are 
not the average of the middle two ordered observations for instances where there are an even number of observations. 4 Other private 
outlets include grocery stores, dukas, general merchandise stores and outlet types that do not fit into any of the mentioned outlet 
categories. 5 In Uganda the sampled sub-districts included two areas located in districts that were undertaking a pilot of subsidised ACT 
in the retail sector. Due to the presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these 
sub-districts than in the rest of the sample (28% and 11% respectively). These areas comprised 1.7% of the total sample of private 
outlets; and while accounting for only 5.4% of the private sector ACT products audited (25 out of 459 ACTs) they accounted for 17.3% of 
ACT products once sampling weights are taken into account (these clusters have high weights because they had a relatively low chance 
of selection under PPS).  As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the 
two pilot areas can give a distorted picture of the average price available across the country as a whole. We have therefore calculated 
the Uganda findings both with and without the subsidised product observations from the 2 pilot areas for ACTs.  Data in table 4.10.2.2 
are presented excluding the subsidised ACT product piloted in these districts. Results where the subsidised ACT products are included are 
provided in table 4.10.2.3. Data collected by the ACTwatch Group during the Uganda 2009 Outlet Survey. www.actwatch.info 
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5. Discussion 
Supply Chain Structure and Wholesaler Characteristics 
Broad-based pyramidal structure of private sector distribution chain with many levels:  The private 
commercial sector distribution chain for antimalarials had a pyramidal shape with a very broad base (i.e. 
there were many distributors at the lower level of the chain supplying retailers and other outlet types).  The 
majority of wholesalers (81.4%) identified in Uganda supplied antimalarials to retailers, and of these, 62.1% 
supplied retailers only.  However, 37.9% of all wholesalers identified supplied antimalarials to retailers and 
other wholesalers, operating across five overlapping levels of the supply chain (intermediate-4, 
intermediate-3, intermediate-2, intermediate-1 and terminal wholesalers). 
 
Most antimalarials pass through three steps from manufacturer to retailer:  As such, the maximum number 
of steps from manufacturers’ factory gate to retailers could be as high as six (manufacturer  intermediate-
4 wholesaler  intermediate-3 wholesaler  intermediate-2 wholesaler  intermediate-1 wholesaler  
terminal wholesaler  retailer).  However, the likely number of steps in the antimalarial supply chain was 
less than six since most wholesalers were observed to sell directly to retailers. As of those supplying 
retailers, only a small percentage (3.9%) were observed to purchase antimalarials directly from 
manufacturers as one of their two top suppliers, most antimalarials were likely to pass through three steps 
from manufacturer to retailer (manufacturer  intermediate wholesaler  terminal wholesaler  retailer).  
 
Multiple factors influence the distribution chain structure:  Uganda’s domestic pharmaceutical industry is 
relatively well developed, and produces a wide range of antimalarial products.  However, until 2006, local 
manufacturers did not produce ACTs, and at the time of this survey, no local manufacturers were producing 
an ACT that was WHO-prequalified. [20-22] This availability of domestically manufactured antimalarials likely 
causes many wholesalers to source some supplies domestically, which is supported by our observation of the 
low number of wholesalers who reported importing antimalarials (23.7%).  Buying domestically has 
additional advantages, such as avoiding the expensive and lengthy bureaucratic requirements of developing 
business relationships with foreign manufacturers and also the high transaction costs of importing, such as 
fees charged by the NDA in order to import foreign medicines and the length of time to process the 
necessary documentation (unpublished data from in-depth interviews conducted with wholesalers in 
Uganda).  
 
The tendency to procure locally produced goods is also supported by data from the ACTwatch Outlet Survey 
which showed that more than a third of all antimalarial products observed during the survey were 
manufactured in Uganda (37%), while 30% originated from India, 10% from China and 7% from Kenya, 
however in terms of volume, products imported from India and China dominate the market. [23]  As in other 
East African countries, many pharmaceutical wholesale businesses are owned and/or operated by 
individuals who may be identified ethnically as South Asian – much of which is the legacy of migration that 
began during British rule in Uganda – and this cultural link between Uganda and India may have facilitated 
the penetration of Indian antimalarial products into Uganda’s market. [24] The hub of pharmaceutical 
manufacturing and wholesaling in Uganda is based in and around Kampala, as are the major ports of 
Entebbe (air and inland marine) and Jinja (inland marine). One of the country’s best roads connects Kampala 
to the land border with Kenya, which is another important foreign source of antimalarials.  However, many 
parts of the country, particularly in the north, are difficult to access by road; so despite Uganda’s relatively 
small land area, regional distribution hubs exist in the major commercial cities across the country.  Several 
instances of vertically integrated wholesale supply chains were noted where importers or large 
pharmaceutical wholesalers based in Kampala also owned and/or operated one or more subsidiary 
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wholesalers in these regional distribution hubs.  Horizontal trading among wholesalers was common in 
Kampala, and similar practices have been observed in other settings. [25] 
 
Transactions between public and private sectors were limited: Only one private outlet reported the National 
Medical Stores, the government’s procurement agency, as one of their two top suppliers of antimalarials – 
and this is likely to have been an error.  However, three public facilities mentioned a private sector source as 
one of their two top antimalarial suppliers, which may reflect some of the problems with the public sector 
supply chain issues noted in other studies. [26] 
 
Wholesaler characteristics:  Wholesale businesses were small with a median of six workers.  Wholesalers 
operating at higher levels of the chain tended to be only slightly larger than those that supplied retailers 
(median of eight vs. five workers, respectively).  Wholesale pharmacies are required to have a registered 
pharmacist on staff who may deputise responsibilities to a professional auxiliary staff member, of which two 
must be employed by the wholesaler.  Therefore, up to half of the employees in a typical wholesale business 
are mandated by regulations.  As regulations stipulate that a pharmacist may be employed by a maximum of 
two businesses, this presents a potential barrier to entering the wholesale and retail market.  Our 
observation that wholesalers had been in operation for a median of eight years may reflect this.  Only 56.6% 
of all wholesalers were observed to sell other products in addition to pharmaceuticals, but these tended to 
be related products, such as toiletries (46.7% of all wholesalers).  Products such as household goods, mobile 
phone credit, cigarettes and food were not commonly sold by wholesalers (all less than 5%). 
 
Business practices within the supply chain: Despite not being very different in size, business practices 
between wholesalers supplying other wholesalers (i.e. intermediate wholesalers) tended to be more 
characteristic of much larger businesses compared to wholesalers supplying retailers (i.e. terminal 
wholesalers).  A higher proportion of intermediate wholesalers reported importing antimalarials (47.9% vs. 
16.4%), buying directly from manufacturers (22.9% vs. 3.9%), delivering to customers (50.0% vs. 26.0%), 
having customers in other countries (41.7% vs. 26.9%), providing credit (87.8% vs. 71.2%), and having a 
broader range of customers.  This could be by virtue of location, as most intermediate wholesalers were 
located in Kampala where the intensity of competition may provide greater incentive to offer more value 
added services to customers, differentiate themselves from other wholesalers, and engage with markets 
further afield. 
 
Licensing and Inspection 
Many wholesalers did not display up-to-date licenses: Despite our observation that virtually all wholesalers 
reported having been visited by an inspector from the National Drug Authority at least once in the 12 
months preceding the interview, only 82.0% of wholesalers were observed to have an up-to-date license, 
which must be renewed annually and prominently displayed on the premises.  Up-to-date licenses in this 
instance included both valid wholesale and retail licenses from the NDA because the bottom-up approach 
used for this study was designed to identify de facto wholesalers (i.e. businesses that sell to other 
businesses); as such, it was expected that some retail outlets, such as grocery stores that should not be 
retailing antimalarials, would purchase antimalarial stock from retail drug outlets, such as pharmacies or 
drug stores.  Another requirement to operate both wholesale and retail businesses is to have a registered 
pharmacist on staff.  Similar to licenses, 88.3% of all wholesalers reported employing a pharmacist.   
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Wholesaler knowledge 
Awareness of AL as first-line treatment is high among wholesalers, but many did not identify AL as the most 
effective treatment for uncomplicated malaria: As Uganda adopted ACTs as first-line treatment policy in 
2004, it may explain why most (86.7%) of the wholesalers interviewed were able to correctly identify AL as 
the government recommended treatment for uncomplicated Pf malaria. However, the percentage of 
wholesalers identifying AL, or any other ACT, as the most effective treatment for uncomplicated malaria in 
both children (40.2%) and adults (50.0%) was much lower.  This may have implications for ACT availability at 
subsequent levels of the supply chain as supplier preferences and recommendations may influence customer 
choices.  These gaps related to ACT acceptance may be partially due to a lack of targeted interventions to 
change wholesaler knowledge, attitudes and behaviours.  In this study, only 15.0% of wholesalers reported 
employing a staff member who had participated in some form of in-service training related to malaria 
treatment in the two years prior to interview.   
 
Availability 
ACT availability was relatively high:  Most of the wholesalers surveyed (88.3%) had an ACT in stock at the 
time of interview, and a similar number (83.3%) reported always having at least one ACT in stock throughout 
the three month period prior to interview.  Just over half of all wholesalers (52.3%) had a WHO-prequalified 
ACT in stock at the time of interview, while non-WHO-prequalified ACTs were stocked by more wholesalers 
(75.0%).   The recommended first-line treatment for uncomplicated malaria, AL, was stocked by 74.0% of all 
wholesalers but only accounted for 13.0% of all antimalarial products stocked by wholesalers and 53.9% of 
all ACTs stocked.  The second most frequently observed ACT stocked by wholesalers after AL was 
dihydroartemisinin piperaquine, which accounted for 5.3% of all antimalarial products stocked by 
wholesalers and 22.3% of all ACTs stocked.  Although local production of ACTs began several years ago in 
2006, many wholesalers were observed to stock a non-WHO-prequalified AL product manufactured in India 
(Lonart), which has a lower purchase price than the brand of AL recommended by the government, Coartem.  
This was also the case at the retail level.  Preference for AL over the locally produced ACT, an ASAQ 
combination listed as the alternative recommended first line treatment for uncomplicated malarial, may also 
partly be due to perceived undesirable side effects associated with amodiaquine among consumers. [27] 
Oral AMT and nAT availability was also relatively high:  The number of wholesalers that stocked nATs 
(89.1%) and oral AMTs (75.8%) was comparable to that for ACTs (88.3%).  In addition, the two most 
frequently observed antimalarials stocked by wholesalers were artemether (an AMT), followed by quinine 
(an nAT) (19.2% and 18.4% of all products stocked by wholesalers, respectively), while SP accounted for 
10.6%, and chloroquine for 9.1%.   More than half (55%) of the artemether products, 72% of the quinine 
products and virtually all of the SP (98%) and chloroquine (97%) products stocked by wholesalers were oral 
formulations, with the remainder in injectable dosage form. 
 
RDT availability was low:  RDTs were stocked by only a few wholesalers, despite their recommended use in 
the case management of fevers: 32.0% of wholesalers supplying other wholesalers, and 17.1% of those 
supplying retailers. 
 
Sales Volumes 
ACTs are being sold by wholesalers in much smaller quantities than nATs:  A range of different indicators 
related to sales volumes demonstrated that only small volumes of ACTs were sold by wholesalers, and sales 
volumes were much lower than for nATs.  Among all wholesalers who sold any antimalarial the week before 
the survey, the median number of AETDs sold was 22.1 (IQR 4.6-95.0) for ACTs, which is less than a tenth of 
the median sales volumes of nATs (310.0 AETDs, IQR 68.9-1578.5).  These high volumes of nATs are driven by 
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sales of SP, which was reported by 37.8% of all wholesalers to be their top selling antimalarial, followed by 
CQ (15.0%) and quinine (12.6%); while AL, for comparison, was the top selling antimalarial among only 10.2% 
of wholesalers.  At retail level, the ACTwatch Outlet Survey observed a similar pattern where SP accounted 
for approximately 40% of total antimalarial volumes sold in pharmacies, private health facilities and drug 
stores. [8] The dominance of SP, CQ and other nATs at all levels of the private sector commercial supply 
chain could be due to familiarity.  Prior to adoption of AL in the malaria treatment guidelines, CQ+SP was the 
recommended first-line treatment.  Also, a CQ+SP combination was the product used at the introduction of 
the Home-Based Management of Fever programme.  This intervention used volunteer Community Medicine 
Distributors to educate caretakers on malaria treatment as well as distribute the treatment itself.  This 
familiarity of other older regimens may also be reflected in our observation that, although knowledge of 
ACTs as the recommended treatment for malaria is generally high, most wholesalers still believe other drugs 
to be more effective treatments.  As we discuss later, the much lower price of these older antimalarials 
compared to ACTs is also another likely driver of demand, particularly as the burden of malaria 
disproportionately falls on Uganda’s poor and numerous rural population. [1]   
 
Volumes of oral AMTs sold among wholesalers are comparable to ACT volumes:  Among all wholesalers, 
median sales volumes of AMTs were comparable to ACT sales volumes (AMTs: 15.0, IQR 1.9-37.8, ACTs: 22.1, 
IQR 4.6-95.0).  Furthermore, despite a ban on oral AMTs having been in place since 2007, AMT tablets were 
still stocked by greater numbers of wholesalers than WHO-prequalified ACTs (92 vs. 67 of 128 wholesalers),  
and sold in volumes that exceeded those for WHO-prequalified ACTs (7.7 AETDs in the past 7 days, IQR 0.0-
18.8 vs. 1.0 AETDs, IQR 0.0-10.0). 
 
Volumes of RDT sold are low:  Of the few wholesalers that were observed to have them in stock (18% of all 
wholesalers), the median number of tests sold during the week preceding the interview was low: 10 tests 
(IQR 0-25). 
 
Price and Mark-ups 
Purchase prices for nAT were much lower than for ACT and AMT:  At wholesale level, the median purchase 
prices for ACT and oral and injectable AMT were many times greater than that for nAT. To demonstrate, the 
median purchase price for nAT was US$ 1.17 (IQR 0.22-3.95) compared to US$ 4.39 (IQR 2.44-7.56) for ACT, 
US$ 5.08 (IQR 3.90-6.25) for AMT tablets and US$ 9.27 (IQR 7.03-11.22) for AMT injectables.  A similar 
pattern was observed at retail level.  For example in drug stores, the median purchase price was US$ 2.27 
(IQR 0.71-3.79) for ACT, US$ 4.92 (IQR 3.79-6.06) for AMT tablets, and US$ 11.36 (IQR 5.52-19.30) for AMT 
injectables; while the median purchase price for nAT was much lower at US$ 0.59 (IQR 0.14-1.99).  This 
partly reflects the large variety of cheap, domestically manufactured nATs that were readily available at 
retail level.   
 
As the sampling strategy used for this study included two rural sub-districts participating in the subsidised 
ACT pilot programme [18], we are able to comment on the possible effect that this intervention may have on 
the purchase prices and mark-ups on WHO-prequalified ACTs.  It is important to note that all of the 
subsidised products encountered were found in drug shops located in the two sampled sub-districts (as 
intended by design), and that the these products accounted for a large proportion of all WHO-prequalified 
products surveyed in the entire national survey (and an even greater proportion once observations were 
weighted to account for variations in sampling probability due to the sampling design).  Once these products 
were taken into account, the median purchase price for ACTs in drug stores was considerably lower, bringing 
the median purchase price for all ACTs very much closer to that of nATs (i.e. for all ACT including subsidised 
 50 
 
products: US$ 0.47 [IQR 0.24-2.84] vs. nAT: US$ 0.59 [IQR 0.14-1.99]), and the median price for WHO-
prequalified ACT tablets much closer to that of nAT tablets (i.e. for WHO-prequalified ACT tablets including 
subsidised products: US$ 0.26 [IQR 0.19-1.80] vs. nAT tablets: US$ 0.21 [IQR 0.08-0.89]).  This is encouraging 
as it suggests that subsidies for ACTs could have the desired effect of reducing end-user prices for quality 
effective antimalarials in drug stores to a level where they can compete with less effective medicines on 
price, so long as wholesalers and retailers do not reduce the value of the subsidy passed onto the consumer 
through excessive mark-ups (see below for additional discussion on mark-ups). 
 
Purchase prices for ACTs and AMTs are comparable at wholesale level for the same dosage forms:  For 
tablets, the median wholesale purchase price per AETD was US$ 4.14 [IQR 2.17-5.86) for ACTs and US$ 5.08 
[IQR 3.90-6.25) for AMTs; and for oral liquid dosage forms, median purchase prices were US$ 12.69 [IQR 
7.81-13.29) for ACTs and US$ 10.15 [IQR 9.37-14.05) for AMTs. This pattern was not observed at retail level 
among private health facilities and drug stores, where median purchase prices for ACTs tended to be lower 
than those for AMTs; however among retail pharmacies, the median purchase prices paid for ACT and AMT 
tablets was similar (US$ 5.32 vs. US$ 5.68, respectively), while the median purchase price paid for ACT oral 
liquids was nearly twice of that paid for AMT oral liquids (US$ 12.62 vs. US$ 6.81, respectively). 
 
Wholesaler mark-ups were lower than retailer mark-ups:  Wholesaler median mid percent mark-ups were 
relatively low and consistent across antimalarial categories (14% on ACTs, 15% on AMTs and 18% on nATs), 
while retail level median mid percent mark-ups were higher, but also fairly consistent across outlet types 
(ACTs: 43%-44%, AMTs: 33%-60%, nAT: 67%-88%). This observed consistency could be a reflection of the 
competitiveness in the wholesale market in Uganda.  At wholesale level, this may also be reflected in our 
finding that wholesalers tended to be clustered in the same locations (i.e. in certain districts in Kampala and 
other major regional commercial centres). At retail level, the public and NGO/mission sectors are also 
important sources of antimalarial treatment and distribute antimalarials free of charge.  This may exert 
additional pressure on private sector retailers to keep margins low.   
 
Wholesale median mid absolute mark-ups were also relatively low, but varied considerably by antimalarial 
type (ACT: US$ 0.68, AMT: US$ 1.09, nAT: US$ 0.24), corresponding to the differences in purchase prices 
across drug categories.  When taking into account observations from the two sub-districts where the ACT 
subsidy programme was being piloted, the additional observations did not have much effect on percentage 
mark-up: for WHO-prequalified ACT, the median mark-up increased from 31.6% when subsidy products were 
excluded to 42.9% when included; compared to 66.7% for nATs.  This translated to median absolute mark-
ups of US$ 0.95 when subsidised products are excluded and US$ 0.19 when included, compared to US$0.44 
for nATs, indicating that – despite the reduced purchase prices resulting from the subsidy noted above – a 
smaller absolute margin from the sale of each subsidised ACT compared to nAT still potentially presents 
wholesalers and retailers with a disincentive to sell the subsidised product.  This may partly be the result of 
retailers adhering to the recommended retail price printed on the subsidised product, restraining the upper 
limit of observed mark-ups. 
 
Large disparities in price and mark-up between AL and SP:  The median purchase price per AETD at wholesale 
level for AL (intermediate wholesalers: US$ 4.97, IQR 2.09-9.04; terminal wholesalers: US$ 3.67, IQR 2.26-
9.04) was at least 20 times the wholesale-level median purchase price for SP (US$ 0.17, IQR 0.12-0.46).  At 
retail level, similar differences in prices between the two antimalarials were also observed.  With respect to 
observed median mid percent mark-ups, these did not differ greatly at wholesale level (AL: 17% vs. SP: 23%); 
however at retail level, there were large differences.  For example, at pharmacies, the median percent mark-
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up for AL was 33% (corresponding to an absolute mark-up of US$ 2.79), while for SP, the median percent 
mark-up was 100% (corresponding to an absolute mark-up of US$ 0.56).  The low price of SP and its high 
demand likely allow retailers to apply high percent mark-ups on this antimalarial; and although the margin 
gained is relatively small, the high volumes being sold indicate that this product is an important revenue 
generator for retailers and wholesalers alike.   
 
Conclusion 
This report has presented a number of important new insights into the private sector market and 
distribution chain for antimalarial drugs in Uganda.  The distribution chain had a pyramid shape comprised of 
multiple levels, with a relatively broad base and narrow top.  While we observed wholesalers to operate over 
5 overlapping levels, most antimalarials are likely to go through 3 steps from manufacturer to retailer (or 4 
steps from manufacturer to end-user).  Although ACTs, and in particular AL, the recommended first-line 
treatment for uncomplicated malaria, were observed to be available in most wholesalers, oral AMTs and 
nATs were observed to have comparable levels of availability among wholesalers.  Furthermore, despite a 
policy promoting ACTs as the first-line therapy for malaria the volumes of ACTs sold were small, particularly 
when compared to sales volumes for nATs.  This may be partially explained by the large difference in 
purchase prices between ACTs and nATs, which is likely to shift demand toward cheaper nATs at lower levels 
of the supply chain and also among consumers, considering that the burden of malaria is disproportionately 
borne by the poor. [1]   
 
Another worrying observation was that, despite the presence of a ban on oral AMT products that has been in 
place since 2007, their typical sales volumes among wholesalers were sizeable and comparable to those for 
WHO-prequalified ACTs.  Wholesale percent mark-ups were observed to be consistent both across 
antimalarial categories and across dosage forms, and tended to be lower than retail-level percent mark-ups 
on antimalarials. For RDTs, their wholesale purchase prices were also low, in fact lower than the purchase 
prices for ACTs, AMTs and nATs.  They were, however, not widely available among wholesalers and sales 
volumes were very low. 
 
When interpreting the findings of this study, it is important to consider that due to the sensitivity of some of 
the topics discussed some responses may be affected by social desirability bias, with respondents answering 
in a way that they think will meet the approval of the interviewer. Also, data for this study were collected in 
2009 and changes to the market since then are likely to have occurred, particularly due to the introduction 
of the AMFm in 2011. 
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6. Appendices 
 
6.1. Supplemental tables for median number of suppository and granule AETDs 
sold 
 
Table 4.8.1a: Median number of AETDs sold during the week preceding the survey (all wholesalers, 
suppositories and granules only) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
N=128
3
 N=48
 
N=105 
All ACT All Median 22.0 58.8 18.9 
IQR 4.8-94.4 15.8-343.6 4.0-57.1 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Non-WHO 
prequalified ACT 
All Median 9.8 30.9 8.9 
IQR 0.0-46.5 3.3-216.0 0.0-37.7 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
AMT All Median 15.0 21.6 14.1 
IQR 2.3-34.8 12.5-125.8 1.9-32.3 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
nAT All Median 304.9 236.2 350.7 
IQR 52.1-1523.7 25.8-3822.6 109.1-1828.3 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid 
diagnostic test for malaria; 2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms 
(tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked 
suppositories or granules, and so few of these product types were observed during the audit, these dosage forms have been 
separated from the tables for other dosage forms provided in the main text. 3 For antimalarials: there were a total of 128 
wholesalers with antimalarial sales volumes (reported or imputed or set as null if did not stock). Note on imputation process for 
antimalarial sales volumes: during the study, 140 wholesalers were identified, of which 127 were interviewed and 4 refused (Table 
1).   Out of the 127 interviewed, 1 did not stock antimalarials at the time of the survey, so their sales volumes were set as zero for 
all antimalarial categories.  The volumes for 14 wholesalers were set as missing for all antimalarial categories: 6 businesses had 
closed down, 2 wholesalers could not be located, 4 refused and had antimalarials in stock, and 2 reported stocking antimalarials 
but no audit sheet information was recorded.  Overall, there were a total of 1326 antimalarials audited, of which 45 (3.4%) had 
missing sales volumes that were imputed using the mi impute pmm command.   
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Table 4.8.2a: Median number of AETDs sold during the week preceding the survey (among 
wholesalers stocking corresponding antimalarial drug category/RDT at the time of the survey, 
suppositories and granules only) 
ANTIMALARIAL TYPE
1
 
Formulation 
WHOLESALER CATEGORIES
3
 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
All ACT All Median 30.0 74.0 25.2 
IQR 10.0-102.7 21.2-344.8 8.9-88.2 
(n) (113) (46) (91) 
Suppository Median 250.0 250.0 - 
IQR 250.0-250.0 250.0-250.0 - 
(n) (1) (1) - 
Granule Median 0.6 19.4 0.4 
IQR 0.1-1.3 1.3-37.5 0.0-0.8 
(n) (8) (2) (6) 
Non-WHO-
prequalified 
ACT 
All Median 19.2 50.6 15.9 
IQR 5.4-91.6 9.3-243.4 5.0-54.4 
(n) (96) (40) (78) 
Suppository Median 250.0 250.0 - 
IQR 250.0-250.0 250.0-250.0 - 
(n) (1) (1) - 
Granule Median 0.6 19.4 0.4 
IQR 0.1-1.3 1.3-37.5 0.0-0.8 
(n) (8) (2) (6) 
AMT All Median 21.3 34.8 18.9 
IQR 10.9-75.0 16.5-200.5 8.6-37.3 
(n) (103) (41) (85) 
Suppository Median 9.4 18.8 0.0 
IQR 0.0-18.8 18.8-18.8 0.0-0.0 
(n) (2) (1) (1) 
Granule Median - - - 
IQR - - - 
(n) - - - 
nAT All Median 398.3 477.9 441.0 
IQR 122.8-2092.8 81.2-4306.3 157.0-2092.8 
(n) (114) (39) (97) 
Suppository Median 131.0 115.5 131.0 
IQR 100.0-166.7 100.0-131.0 100.0-166.7 
(n) (3) (2) (3) 
Granule Median - - - 
IQR - - - 
(n) - - - 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid 
diagnostic test for malaria.  2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage 
forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers 
stocked suppositories or granules, and so few of these product types were observed during the audit, these dosage forms 
have been separated from the tables for other dosage forms provided in the main text. 3 (n) is the number of wholesalers 
at a given level who stocked antimalarials for corresponding drug category. 
 
  
 54 
 
6.2. Range of health and non‐health retail outlets selling antimalarials in Uganda 
 
Public Health Facilities  N Description 
National / Regional referral hospital  3 
These government-run facilities provide free prescription medicines, 
medical consultations and diagnoses. They are staffed by qualified 
health practitioners. 
 
Parish-level facilities provide preventive and curative health services 
to outpatients. In addition to these services, sub-county facilities 
provide some inpatient care such as maternity, and in theory have 
laboratory services available. County-level health centres provide the 
same services as HC III, but are also equipped for emergency surgery 
procedures, including blood transfusion.  
 
District hospitals offer services available in HC IV, in addition to 
assistance to community-based care programmes and in-service 
training for staff. Regional referral hospitals have provision for 
specialist inpatient and outpatient services such ENT, dentistry, 
radiology and intensive care wards. In addition to these facilities, the 
2 national referral hospitals are involved in teaching medical students 
and conducting research (UMOH, 2005).  
District hospital  8 
Health centre IV: County  49 
Health centre III: Sub-county  198 
Health centre II: Parish  267 
   
Community medicine distributors N Description 
Community medicine distributor  90 
Provide free non-prescription medicines, including ACTs under the 
Home-Based Management of Fever (HBMF) program.  
   
Private not-for-profit facilities N Description 
Non-Governmental Organization 
(NGO) and Missionary hospital  
11 
These facilities provide prescription medicine at a nominal price 
following medical consultation or diagnosis. They are usually staffed 
with qualified health practitioners, though some smaller clinics run by 
NGOs have less well-qualified staff.  
   
Private for-profit facilities N Description 
Private clinic / domiciliary / midwife  208 
These for-profit facilities are staffed by qualified health practitioners 
and generally include a consultation / examination room. They are 
licensed by the Ministry of Health (MOH), the Uganda Medical and 
Dental Practitioners Association, and/or the Nurses and Midwives 
Council. 
 
These outlets sell prescription-only, licensed, and over-the-counter 
medicines at a commercial rate, and in accordance with the laws on 
licensed pharmacies and/or licensed drug sellers.   
 
An unknown proportion of these outlets are not registered by the 
Ministry of Health.  
  
  
Pharmacies N Description 
Pharmacy  97 
Licensed and highly regulated by the National Drug Authority (NDA), 
pharmacies sell prescription medicines at a commercial rate. Their 
staff must include at least one qualified pharmacist, and many of the 
other staff are also qualified health practitioners. They sell all classes 
of medicines, including class A (narcotics), which are restricted to 
prescription-only sale by a registered pharmacist or licensed 
pharmacy.  
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Drug Stores N Description 
Drug store  398 
These outlets are smaller than pharmacies, and typically stock a 
smaller range of medicines. In theory they are licensed by the NDA, 
although an unknown proportion of these outlets are not registered. 
Drug stores sell class C (non-prescription but licensed) medicines and 
over-the-counter medicines at a commercial rate. NDA-licensed drug 
stores are staffed by qualified health dispensers or practitioners (e.g. 
enrolled nurses, clinical officers).  
   
General Retailers N Description 
Grocery stores / Dukas / General 
merchandise stores  
3,747 Businesses/points of sale that sell fast moving consumer goods (e.g. 
food, household products), in addition to some medicines (most often 
antipyretics). Drugs sold at these locations are not regulated.  Kiosks  180 
Other  8 
This category includes a small number of traditional healers (3) and 
mobile shops/hawkers (5) that were enumerated.  
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6.3. Calculating AETDs:  antimalarial treatment and equivalent adult treatment dose 
Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Amodiaquine 1800mg   WHO Use of Antimalarials, 2001 
Amodiaquine-Sulfadoxine-
Pyrimethamine 
1800mg Amodiaquine  WHO Model Formulary, 2008 
Arteether 1050mg   WHO Use of Antimalarials, 2001 
Artemether 960mg   WHO Use of Antimalarials, 2001 
Artemether-Lumefantrine 480mg Artemether  WHO Model Formulary, 2008 
Artemisinin-Naphthoquine 2400mg Artemisinin Manufacturer Guidelines for this product 
are 1000mg Artemisinin in a single dose. 
Such a short ACT regimen is highly suspect. 
This treatment dose is based upon the WHO 
Artemisinin-MQ recommendation of a total 
dose of 40mg/kg. 
WHO Use of Antimalarials, 2001 
Artemisinin-Piperaquine 576mg Artemisinin Treatment dose based on Artemisinin-
Piperaquine-Primaquine value, below. 
As below 
Artemisinin-Piperaquine-
Primaquine 
576mg Artemisinin  Tangpukdee, N. et al. 2008. Efficacy of 
Artequick versus artesunate-mefloquine in 
the treatment of acute uncomplicated 
falciparum malaria in Thailand. The 
Southeast Asian Journal of Tropical 
Medicine and Public Health. 39(1): 1-8 
http://imsear.hellis.org/handle/12345678
9/33676  
Artesunate 960mg   WHO Use of Antimalarials, 2001 
Artesunate-Amodiaquine 600mg Artesunate  Manufacturer Guidelines 
(Winthrop/Coarsucam – Sanofi Aventis) 
Artesunate-Halofantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Artesunate-Lumefantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Mefloquine 600mg Artesunate  Manufacturer Guidelines 
(Artequin Adult – Mepha) 
Artesunate-Piperaquine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Pyronaridine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Sulfadoxine-
Pyrimethamine 
600mg Artesunate  Manufacturer Guidelines 
(Co-arinate – Dafra) 
Atovaquone-Proguanil 3000mg Atovaquone  Manufacturer Guidelines 
(Malanil – GSK) 
Chloroquine 1500mg   WHO Model Formulary, 2008 
Chloroquine-Sulfadoxine-
Pyrimethamine 
1500mg Chloroquine  WHO Model Formulary, 2008 
Chlorproguanil-Dapsone 360mg Chlorproguanil  Manufacturer Guidelines 
(LapDap – GSK) 
Dihydroartemisinin 480mg   Manufacturer Guidelines 
(Cotecxin – Holleypharm; MALUether – 
Euromedi) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Dihydroartemisinin-
Amodiaquine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Halofantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Lumefantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Piperaquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Duo-cotecxin – Holleypharm) 
Dihydroartemisinin-
Piperaquine-Trimethoprim 
256mg Dihydroartemisinin  Manufacturer Guidelines 
(Artecxin – Medicare Pharma; Artecom – 
Ctonghe) 
Dihydroartemisinin-
Pyronaridine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Sulfadoxine-Pyrimethamine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Dalasin – Adams Pharma) 
Dihydroartemisinin-
Mefloquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Meflodisin – Adams Pharma) 
Halofantrine 1500mg  This dose is for halofantrine hydrochloride 
as the strength is normally reported in this 
manner. The total dose for halofantrine 
base is 1398 mg. 
Manufacturer Guidelines 
(Halfan – GSK) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Hydroxychloroquine 2000mg   Manufacturer Guidelines 
(Plaquenil – Sanofi Aventis) 
Mefloquine 1000mg   WHO Use of Antimalarials, 2001 
Mefloquine-Sulfadoxine-
Pyrimethamine 
1000mg Mefloquine  WHO Use of Antimalarials, 2001 
Primaquine 45mg  This dose is for the gametocytocidal 
treatment of P. falciparum. 
WHO Model Formulary, 2008 
Quinacrine 2212mg  Recommendations for malaria treatment 
are very dated. This value is the treatment 
regimen for giardiasis, which has also been 
used in the treatment for malaria.  
Gardner, T. B. and Hill, D. R. 2001. 
Treatment of Giardiasis. Clinical 
Microbiology Reviews. 14(1): 114-128 
http://cmr.asm.org/cgi/content/full/14/1/
114#T2  
Quinimax 10500mg   Manufacturer Guidelines 
(Quinimax – Sanofi Aventis) 
Quinine 12600mg  This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Quinine-Sulfadoxine-
Pyrimethamine 
12600mg Quinine This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Sulfadoxine-Pyrimethamine 1500mg Sulfadoxine  WHO Model Formulary, 2008 
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6.4. Rationale & method to calculate weights and how to use weights to 
calculate indicators 
Study design 
During the 2009 ACTwatch Outlet Survey in Uganda, stratification based on malaria endemicity 
allowed for two appropriate domains for the outlet survey, high endemicity and low endemicity. A 
one-stage probability proportional to size (PPS) technique was then used to select 19 clusters (sub-
counties) within each domain, with the sub-county population as the measure of size. As a result of 
this approach, 3 sub-counties were randomly selected from Kampala district. The smallest of these 
sub-counties had a population of 240,624 and so in all three cases a Parish was further randomly 
selected (by SRS) from each of the selected sub-counties in Kampala. The three parishes were the 
administrative unit in which the census of outlets was conducted. 
 
Booster Sample 
A booster sample of public health facilities (PHFs) comprised all PHFs in the county in which a 
selected sub-county fell. For the booster sample, PHFs included referral hospitals, health centers, 
and health posts, but excluded Community Medicine Distributers. A booster sample of Part-one 
Pharmacies (POPs) comprised all POPs in the district in which a selected sub-county fell. No booster 
sample was conducted for the 3 parishes in Kampala district. 
A note on county and district boundaries 
During fieldwork the counties and districts visited for the booster sample occasionally differed from 
those defined in the 2002 census in terms of the sub-counties included by their boundaries. In each 
case, these ‘new’ counties and districts matched those listed in the 2006 Health Facility Inventory in 
terms of the sub-counties included by their boundaries. In such instances, county and district 
population totals were calculated based on the ‘new’ boundaries and the sub-counties they include, 
using sub-county population data from the 2002 census. These ‘new’ population totals match the 
areas visited by interviewers based on the list of sub-counties in the dataset. Note that this problem 
did not occur at the sub-county level and thus the original sampling method and all non-booster 
weighting is unaffected by any county and district-level boundary changes. 
 
Weighting approach 
Weights were calculated differently for PHFs, POPs, and other outlet types, and were specific to 
analysis type, but generally involved the inverse of the selection probability and corresponding 
population size. We used sub-county populations for non-PHFs non-POPs, and for analysis involving 
only the non-booster sample (i.e. estimation of volumes for all outlet types). County populations 
were used for PHF outlet types, and district populations for POP outlet types, where analysis 
included the booster sample (i.e. availability and price). Although coded on the field questionnaire as 
PHFs, Community Medicine Distributors were absent from the booster sample and thus weighted 
throughout as a non-PHF outlet type. A correction factor was included in the weighting formula for 
booster outlets. This allowed us to account for potentially different approaches taken to reach 
outlets in the larger booster areas (counties and districts as opposed to sub-counties). Weights were 
not scaled. This was partly for convenience, but also driven by the key indicators being proportions 
and medians, which are invariant under scaling. In analysis the weights indicate the probability of 
selection, and are invoked using the pweight command in Stata. 
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The weight calculations are summarized as follows: 
 
Availability and Price analysis (excluding Kampala): 
 
i. All PHFs enumerated in a county; 
 
county in the  visitedPHFs ofNumber 
countyfor  frame samplein  listed PHFs ofNumber 
PopulationCounty   stratumin   visitedcounties ofNumber 
Population Stratum


iWeight
 
 
where the number of counties visited is 19 for high endemicity and 16 for low endemicity. 
 
ii. All POPs enumerated in a district; 
 
district in the  visitedPOPs ofNumber 
districtfor  frame samplein  listed POPs ofNumber 
PopulationDistrict   stratumin   visiteddistricts ofNumber 
Population Stratum


iWeight
 
 
where the number of districts visited is 19 for high endemicity and 15 for low endemicity. 
 
iii. Non-PHF non-POP outlets (including Community Medicine Distributors) enumerated in a 
selected sub-county; 
 
PopulationSubCounty 19
Population Stratum

iWeight
 
 
Volumes analysis (excluding Kampala): 
All outlets enumerated in a selected sub-county (non-booster sample); 
PopulationSubCounty 19
Population Stratum

iWeight
 
 
Availability, Price, and Volumes analysis for 3 Parishes in Kampala: 
 All outlets enumerated in the 3 parishes falling in Kampala district; 
1
SubCounty selectedin  Parishes ofNumber 
PopulationSubCounty   19
Population Stratum


iWeight
 
 
where the number of parishes is 19 for Kawmepe sub-county, 21 for Makindye sub-county, 
and 23 for Nakawa sub-county. 
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Data provided for weight estimation 
i. Population size at sub-county level for the malaria endemic areas with strata specified 
accordingly (Ref: Uganda National Census Frame, 2002) 
ii. A list of the selected sub-counties in the two strata 
iii. List of PHFs (referral hospitals, health centers, and health posts) at Parish level, with sub-
county, county and district names also indicated 
(Ref: Health Facility Inventory, October 2006, Uganda MoH) 
iv. List of registered pharmacies (POPs) by district, dated 2009 
 
Tables 
The tables on the following pages list the population figures and sampling frame PHF and POP counts 
used to calculate weights. The four tables presented are: 
 
6.4.1.  PHF weights by county for availability & price estimates (excludes Kampala) 
6.4.2.  POP weights by district for availability & price estimates (excludes Kampala) 
6.4.3.  Non-PHF non-POP weights by sub-county for availability & price estimates (includes Kampala) 
6.4.4.  All non-booster outlet weights by sub-county for volume estimates (includes Kampala) 
 
Note on Table 6.4.2: Boundary differences for booster districts between the 2002 census, and the 
2009 List of Registered Pharmacies by District and areas covered by fieldwork, are highlighted under 
the column marked District. For example, in the 2002 census the counties of Ibanda and Kazo are 
contained within Mbarara district. In the 2009 list, and for fieldwork purposes, they are autonomous 
districts. The District Population is that which represents the areas covered by fieldwork, and will 
differ from those given in the 2002 census. 
 
Note on Tables 6.4.3 and 6.4.4: It is clear from the formulas above that the weights in Tables 3 and 4 
are identical. Both tables are presented here for the sake of completeness when talking about 
weights for different analysis types. 
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Table 6.4.1: PHF weights by county for availability and price estimates (excludes Kampala) 
 
County 
Stratum 
(High / Low 
Endemicity) 
Strata 
Population 
County 
Population 
Total PHFs 
in County 
(Sample 
frame) 
Number of 
PHFs 
visited 
Weight 
(Availability 
and Price) 
Nakaseke High 16,033,410 137,278 16 19 5.18 
Masaka Municipal High 16,033,410 67,768 7 5 17.43 
Kassanda High 16,033,410 201,052 14 11 5.34 
Mukono High 16,033,410 257,857 19 21 2.96 
Kyotera High 16,033,410 140,580 21 15 8.40 
Bukooli North High 16,033,410 116,843 15 7 15.48 
Kigulu High 16,033,410 235,866 22 21 3.75 
Bugabula High 16,033,410 230,870 19 12 5.79 
Bukedea High 16,033,410 122,433 7 7 6.89 
Budaka High 16,033,410 136,489 11 9 7.56 
West Budama North High 16,033,410 107,163 15 11 10.74 
Kole High 16,033,410 165,922 9 7 6.54 
Koboko High 16,033,410 129,148 8 5 10.45 
Kilak High 16,033,410 119,430 17 10 12.01 
Moroto High 16,033,410 163,047 14 9 8.05 
Aruu High 16,033,410 142,320 14 10 8.30 
Igara High 16,033,410 205,671 18 21 3.52 
Busongora High 16,033,410 276,841 41 28 4.46 
Kibale High 16,033,410 155,935 14 12 6.31 
Busiro Low 7,770,989 365,306 32 26 1.64 
Kyadondo Low 7,770,989 542,682 27 23 1.05 
Bubulo Low 7,770,989 262,566 14 15 1.73 
Bungokho Low 7,770,989 261,440 11 15 1.36 
Budadiri Low 7,770,989 185,819 19 10 4.97 
Lamwo Low 7,770,989 115,345 17 11 6.51 
Bugahya Low 7,770,989 198,833 22 16 3.36 
Ndorwa Low 7,770,989 153,595 31 27 3.63 
Bunyangabu Low 7,770,989 127,062 14 14 3.82 
Bugangaizi Low 7,770,989 108,357 11 9 5.48 
Bufumbira Low 7,770,989 220,312 28 28 2.20 
Ibanda Low 7,770,989 198,635 32 29 2.70 
Kazo Low 7,770,989 111,589 17 17 4.35 
Rwampara Low 7,770,989 131,962 18 20 3.31 
Kinkiizi Low 7,770,989 204,732 24 24 2.37 
Kyaka Low 7,770,989 110,925 13 11 5.17 
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Table 6.4.2: POP weights by district for availability and price estimates (excludes Kampala) 
 
District 
Stratum 
(High / Low 
Endemicity) 
Strata 
Population 
District 
Population 
Total POPs 
in Disrict 
(Sample 
frame) 
Number of 
POPs visited 
Weight 
(Availability 
and Price) 
Luwero High 16,033,410 478,595 1 1 1.76 
Masaka High 16,033,410 770,662 10 4 2.74 
Mubende High 16,033,410 689,530 4 4 1.22 
Mukono High 16,033,410 795,393 8 6 1.41 
Rakai High 16,033,410 470,365 3 2 2.69 
Bugiri High 16,033,410 412,395 0 0 - 
Igana High 16,033,410 708,690 4 5 0.95 
Kamuli High 16,033,410 722,090 3 2 1.75 
Kumi High 16,033,410 122,433 0 0 - 
Pallisa High 16,033,410 136,489 0 0 - 
Tororo High 16,033,410 536,888 3 1 4.72 
Apac High 16,033,410 683,993 0 0 - 
Arua High 16,033,410 833,928 6 7 0.87 
Gulu High 16,033,410 458,967 6 3 3.68 
Lira High 16,033,410 741,240 10 8 1.42 
Pader High 16,033,410 326,338 0 0 - 
Bushenyi High 16,033,410 754,219 1 1 1.12 
Kasese High 16,033,410 523,033 2 3 1.08 
Kamwenge High 16,033,410 263,730 0 1 3.20 
Wakiso Low 7,770,989 907,988 21 10 1.20 
Mbale (Bubutu) Low 7,770,989  10 0 - 
Mbale (Busiu) Low 7,770,989 718,239 10 4 1.80 
Sironko Low 7,770,989 283,092 0 1 1.83 
Kitgum Low 7,770,989 282,375 1 2 0.92 
Hoima Low 7,770,989 343,618 6 6 1.51 
Kabale Low 7,770,989 458,318 3 3 1.13 
Kabarole Low 7,770,989 356,914 8 7 1.66 
Kibaale Low 7,770,989 405,882 1 2 0.64 
Kisoro Low 7,770,989 220,312 1 0 - 
Mbarara (Ibanda) Low 7,770,989 198,635 1 2 1.30 
Mbarara (Kazo)  Low 7,770,989  0 0 - 
Mbarara Low 7,770,989 777,132 20 8 1.66 
Kanungu Low 7,770,989 204,732 0 0 - 
Kyenjojo Low 7,770,989 377,171 2 1 2.75 
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Table 6.4.3: Non-PHF non-POP weights by sub-county for availability and price estimates 
(Includes Kampala – refer to weighting section above for details of Kampala-specific weighting) 
 
Sub-county 
Stratum  
(High / Low 
Endemicity) 
Strata 
Population 
Sub-county 
Population 
Weight 
(Availability 
and Price) 
Kikamulo High 16,033,410 22,078 38.22 
Nyendo/Senyange High 16,033,410 29,562 28.55 
Kassanda High 16,033,410 58,828 14.34 
Nama High 16,033,410 33,004 25.57 
Kalisizo High 16,033,410 27,847 30.30 
Kapyanga High 16,033,410 42,553 19.83 
Namungalwe High 16,033,410 28,061 30.07 
Balawoli High 16,033,410 35,000 24.11 
Kachumbala High 16,033,410 36,767 22.95 
Naboa High 16,033,410 17,337 48.67 
Nagongera High 16,033,410 28,907 29.19 
Alito High 16,033,410 50,549 16.69 
Kuluba High 16,033,410 18,030 46.80 
Lamogi High 16,033,410 25,426 33.19 
Apala High 16,033,410 30,605 27.57 
Puranga High 16,033,410 14,396 58.62 
Nyabubare High 16,033,410 35,111 24.03 
Maliba High 16,033,410 37,204 22.68 
Kahunge High 16,033,410 50,622 16.67 
Bwaise II (Kampala) Low 7,770,989 262,165 29.64 
Bukasa (Kampala) Low 7,770,989 303,171 28.33 
Kiwatule (Kampala) Low 7,770,989 240,624 39.09 
Ssisa Low 7,770,989 45,624 8.96 
Nabweru Low 7,770,989 104,400 3.92 
Bubutu Low 7,770,989 38,928 10.51 
Busiu Low 7,770,989 25,746 15.89 
Buyobo Low 7,770,989 18,028 22.69 
Palabek Gem Low 7,770,989 12,639 32.36 
Buhanika Low 7,770,989 20,050 20.40 
Kaharo Low 7,770,989 17,974 22.76 
Buheesi Low 7,770,989 32,600 12.55 
Nalweyo Low 7,770,989 20,756 19.71 
Muramba Low 7,770,989 28,189 14.51 
Nyamarebe Low 7,770,989 20,685 19.77 
Buremba Low 7,770,989 27,324 14.97 
Rugando Low 7,770,989 22,802 17.94 
Kanyantorogo Low 7,770,989 16,643 24.57 
Kyegegwa Low 7,770,989 25,111 16.29 
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Table 6.4.4: All non-booster outlet weights by sub-county for volume estimates 
(Includes Kampala – refer to weighting section above for details of Kampala-specific weighting) 
 
Sub-county 
Stratum  
(High / Low 
Endemicity) 
Strata 
Population 
Sub-county 
Population 
Weight 
(Availability 
and Price) 
Kikamulo High 16,033,410 22,078 38.22 
Nyendo/Senyange High 16,033,410 29,562 28.55 
Kassanda High 16,033,410 58,828 14.34 
Nama High 16,033,410 33,004 25.57 
Kalisizo High 16,033,410 27,847 30.30 
Kapyanga High 16,033,410 42,553 19.83 
Namungalwe High 16,033,410 28,061 30.07 
Balawoli High 16,033,410 35,000 24.11 
Kachumbala High 16,033,410 36,767 22.95 
Naboa High 16,033,410 17,337 48.67 
Nagongera High 16,033,410 28,907 29.19 
Alito High 16,033,410 50,549 16.69 
Kuluba High 16,033,410 18,030 46.80 
Lamogi High 16,033,410 25,426 33.19 
Apala High 16,033,410 30,605 27.57 
Puranga High 16,033,410 14,396 58.62 
Nyabubare High 16,033,410 35,111 24.03 
Maliba High 16,033,410 37,204 22.68 
Kahunge High 16,033,410 50,622 16.67 
Bwaise II (Kampala) Low 7,770,989 262,165 29.64 
Bukasa (Kampala) Low 7,770,989 303,171 28.33 
Kiwatule (Kampala) Low 7,770,989 240,624 39.09 
Ssisa Low 7,770,989 45,624 8.96 
Nabweru Low 7,770,989 104,400 3.92 
Bubutu Low 7,770,989 38,928 10.51 
Busiu Low 7,770,989 25,746 15.89 
Buyobo Low 7,770,989 18,028 22.69 
Palabek Gem Low 7,770,989 12,639 32.36 
Buhanika Low 7,770,989 20,050 20.40 
Kaharo Low 7,770,989 17,974 22.76 
Buheesi Low 7,770,989 32,600 12.55 
Nalweyo Low 7,770,989 20,756 19.71 
Muramba Low 7,770,989 28,189 14.51 
Nyamarebe Low 7,770,989 20,685 19.77 
Buremba Low 7,770,989 27,324 14.97 
Rugando Low 7,770,989 22,802 17.94 
Kanyantorogo Low 7,770,989 16,643 24.57 
Kyegegwa Low 7,770,989 25,111 16.29 
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